Document:

Call Option/Note Redemption Agreement

 Exhibit 10.10 

EXECUTION VERSION 
 CALL OPTION/NOTE REDEMPTION AGREEMENT 
 This CALL OPTION/NOTE REDEMPTION AGREEMENT (this “Agreement”) is dated as of August 16, 2012 (the “Effective Date”) and is entered into by and between NextWave
Wireless LLC (“NextWave”) and NextWave Holdco LLC (the “Company”), on the one hand, and Wilmington Trust, National Association as noteholder representative (the “Noteholder Representative”) and the
parties listed on Schedule A attached hereto (each, a “Noteholder” and, collectively, the “Noteholders”), on the other hand. 
 RECITALS 
 WHEREAS, NextWave, NextWave Wireless Inc.
(“Listco”), certain guarantors party thereto, certain purchasers party thereto and The Bank of New York Mellon as Collateral Agent, previously entered into that certain Third Lien Subordinated Exchange Note Exchange Agreement dated
as of October 9, 2008 (the “Original Note Agreement”), pursuant to which the original purchasers acquired $478,294,966 aggregate Stated Value of Third Lien Subordinated Secured Convertible Notes (the “Original
Notes”) from Listco in exchange for certain shares of series A preferred stock of Listco in an exchange transaction pursuant to Section 3(a)(9) of the Securities Act; 

WHEREAS, as of the date hereof, the aggregate principal amount of outstanding Original Notes, all of which are held by the
Noteholders, is $761,887,512.00; 
 WHEREAS, the Noteholders previously entered into a Forbearance Agreement dated
as of August 1, 2012 (the “Forbearance Agreement”) for the benefit of Listco, NextWave and certain other parties named therein, pursuant to which the Noteholders agreed to temporarily forbear from taking any Enforcement Actions
(as defined in the Forbearance Agreement) against NextWave and Listco based upon the Covered Defaults (as defined in the Forbearance Agreement) under the Original Note Agreement, but only to the extent and on the terms and conditions expressly set
forth therein; 
 WHEREAS, in connection with the Forbearance Agreement, the parties to the Original Note Agreement have
agreed that Listco shall assign to the Company a portion of the obligations under the Original Notes in an aggregate principal amount equal to $436,887,512.00, and the Company has agreed to assume such portion of the obligations under the Original
Notes, which obligations will be evidenced by the Notes (as defined below) to be issued on the terms and conditions provided for in the Note Exchange Agreement (as defined below); 

WHEREAS, simultaneously herewith, Listco, NextWave, the Company, the Guarantors party thereto, the Collateral Agent (as defined
therein), and the Noteholders have entered into an Amended and Restated Spinco Third Lien Subordinated Exchange Agreement dated as of the date hereof (the “Note Exchange Agreement”); 

WHEREAS, simultaneously herewith, pursuant to the Note Exchange Agreement the Company has issued to the Noteholders Spinco Third
Lien Subordinated Secured Notes Due 

  
 1 

 
2013 (each, a “Note” and, collectively, the “Notes”) in an aggregate principal amount equal to $436,887,512.00; 

WHEREAS, the Noteholders have agreed that the Notes shall be subject to the Forbearance Agreement (but only to the extent and on
the terms and conditions expressly set forth therein); 
 WHEREAS, simultaneously herewith, Listco, NextWave, the
Company, the Guarantors party thereto, the Collateral Agents, and the Noteholders have entered into an Amended and Restated Intercreditor Agreement dated as of the date hereof (the “Intercreditor Agreement”); 

WHEREAS, NextWave owns 100% of the Company Interests (as defined below); and 

WHEREAS, in consideration of the Noteholders entering into the Noteholder Agreements (as defined below) and other agreements
related thereto, and in accordance therewith, NextWave has agreed to grant to the Noteholder Representative, for and on behalf of the Noteholders, the option to acquire the Company Interests as provided herein. 

NOW, THEREFORE, in consideration of the premises and the mutual covenants, agreements and conditions contained herein, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound hereby, agree as follows: 
 SECTION 1 
 DEFINITIONS 

1.1 Definitions. The following terms, when used in this Agreement, have the following meanings, unless the context otherwise
indicates: 
 “Acquiror Note Purchase Agreement” shall mean that certain Note Purchase Agreement, dated as of
August 1, 2012, by and among AT&T, Inc. (the “Acquiror”), the consenting holders listed on Schedule I thereto and the Holder Representative (as defined therein). 

“Amount Owing” shall mean, with respect to any Note, the aggregate amount owing (including all principal and interest,
however accrued, whether as payment in kind interest or otherwise) under such Note. 
 “Bankruptcy Code”
means Title 11 of the United States Code entitled “Bankruptcy”, as now and hereafter in effect, or any successor statute. 
 “Bankruptcy Exercise Condition” shall mean a condition that is satisfied upon the occurrence of each of the following: (i) the Governance Effective Date and (ii) the filing by
or against Listco, NextWave or the Company of a voluntary or involuntary petition under the Bankruptcy Code (other than pursuant to a breach of Section 4.1(c), Section 4.1(d) or Section 4.1(e) of the Acquiror Note Purchase Agreement).

  
 2 

 “Board of Directors” shall mean the board of directors of the Company.

 “Call Exercise Cash Payment” shall mean the payment of $25 million by the Funding Noteholders for the
benefit of the common equity holders of Listco (which Call Exercise Cash Payment will not constitute a payment on account of any collateral of the Noteholders or an asset of any of the Noteholders, and the Noteholders hereby agree that such Call
Exercise Cash Payment will not be subject to any mandatory prepayment or restrictions on dividends). 
 “Company
Interests” shall mean all of the limited liability company interests of the Company, which, for the avoidance of doubt, shall include any and all interests in the Company acquired or beneficially owned by NextWave or any of its affiliates
on or after the date hereof. 
 “Company Members” shall mean the members of the Company after the Closing (as
defined below). 
 “Funding Noteholders” shall mean the Noteholders that affirmatively vote in favor of the
Noteholder Direction and that fund their pro rata share, or any additional share if any other Noteholder fails to fund its pro rata share, of the Call Exercise Cash Payment. 
 “Governance Effective Date” shall mean the date on which the transfer of control of the Company from NextWave to the Noteholders is approved by the United States Federal Communications
Commission (the “FCC”). 
 “Merger Agreement” shall mean that certain Agreement and Plan of
Merger, dated as of August 1, 2012, by and among the Acquiror, Rodeo Acquisition Sub Inc. and Listco. 
 “Merger
Closing” shall mean the Closing as defined in the Merger Agreement and pursuant to and in accordance with the provisions thereof. 
 “Merger Exercise Condition” shall mean a condition that is satisfied upon the occurrence of each of the following: (i) the Governance Effective Date and (ii) the satisfaction or
waiver of all conditions in Section 6.1 (other than Section 6.1(c)) and Section 6.2 of the Merger Agreement, other than those conditions which by their nature can only be satisfied at the Merger Closing. 

“Merger Termination Condition” shall mean a condition that is satisfied upon delivery of the Noteholder Direction to the
Noteholder Representative at any time following the occurrence of each of the following: (i) the Governance Effective Date and (ii) the termination of the Merger Agreement (in accordance with its terms). 

“Note Redemption” shall mean the redemption of the then outstanding Notes (if any) in full pursuant to and in accordance
with Article VIII of the Note Exchange Agreement. 

  
 3 

 “Noteholder Agreements” shall mean the Forbearance Agreement, the Note
Exchange Agreement and the Intercreditor Agreement. 
 “Noteholder Direction” shall mean a writing signed by
the Required Noteholders and delivered to the Noteholder Representative (with a copy to each Noteholder) directing the Noteholder Representative to exercise the Call Option for and on behalf of the Noteholders and setting forth each
Noteholder’s pro rata share of the Call Exercise Cash Payment. 
 “Operating Agreement” shall mean the
Limited Liability Company Agreement of the Company dated as of August 8, 2012, as amended from time to time. 

“Required Members” shall mean, at any time after the Closing, Company Members then holding 75% or more of the Company
Interests. 
 “Required Noteholders” shall mean Noteholders holding 75% or more of the Amount Owing under the
Notes; provided, that in the event there are not sufficient consenting Noteholders necessary to meet such 75% threshold in circumstances where one or more Noteholders has requested the Noteholders to consent to a Noteholder Direction, any consenting
Noteholders may purchase, pro rata among such consenting Noteholders (or, if all consenting Noteholders are not willing to purchase their pro rata share, as otherwise agreed among such consenting Noteholders that are willing to purchase additional
Notes), all of the Notes held by any non-consenting Noteholder(s), together with all rights and obligations with respect thereto, in order to reach or exceed such 75% threshold and give the requested Noteholder Direction, by the payment to such
non-consenting Noteholder(s) in cash of the Amount Owing under such Notes, upon which the Notes held by such non-consenting Noteholder(s) shall be automatically transferred to the Noteholders who funded the payment to such non-consenting
Noteholder(s) pro rata in accordance with the amount so funded, which shall then be included as consenting for purposes of calculating the 75% threshold and the giving of the Noteholder Direction. Any such purchase and transfer shall be notified in
writing to the Noteholder Representative by any such consenting Noteholder together with a written certification by such Noteholder of such Noteholder’s pro rata share of the Amounts Owing following any such purchase and transfer; provided
that, in no event shall the Noteholder Representative be deemed to have knowledge of any purchase of Note(s) by any consenting Noteholder(s) from any non-consenting Noteholder(s) absent receipt of written notice from any such consenting
Noteholder(s) of such purchase. 
 SECTION 2 
 CALL OPTION 
 2.1 Call Option. 

(a) NextWave hereby grants to, and the Noteholder Representative shall have, for and on behalf of the Noteholders, the option (the
“Call Option”), exercisable as provided in Section 2.2 below, to purchase 100% of the Company Interests. 

  
 4 

 (b) If the Merger Exercise Condition is satisfied prior to the satisfaction of the Merger
Termination Condition or the Bankruptcy Exercise Condition, the Note Redemption shall automatically occur pursuant to and in accordance with Section 8.1(a) of the Note Exchange Agreement (the “Automatic Redemption”) immediately
prior to the Merger Closing. Such Automatic Redemption shall not require any further approval of any kind by any person, including, without limitation, the Noteholder Representative, the Required Noteholders, the Board of Directors or any member of
the Company. The Company shall provide written notice of (i) the satisfaction or waiver of all conditions in Section 6.1 (other than Section 6.1(c)) and Section 6.2 of the Merger Agreement, other than those conditions which by
their nature can only be satisfied at the Merger Closing, and (ii) the date and time on which Listco and the Acquiror intend for the Merger Closing to occur, as far in advance as reasonably practicable (as well as updates to the extent that
such date and time changes). 
 2.2 Exercise of the Call Option. 

(a) If the Merger Termination Condition is satisfied prior to the satisfaction of the Merger Exercise Condition or the Bankruptcy
Exercise Condition, the Noteholder Representative shall, upon the receipt of the Noteholder Direction, exercise the Call Option, for and on behalf of the Noteholders, by delivering a written notice (an “Exercise Notice”), signed by
the Noteholder Representative, to NextWave stating that the Call Option is exercised, and the Note Redemption shall automatically occur pursuant to and in accordance with Section 8.1(d) of the Note Exchange Agreement at the Closing. Such
exercise shall not require any further approval of any kind by any person, including, without limitation, the Noteholder Representative, the Required Noteholders, the Board of Directors or any member of the Company. 

(b) If the Bankruptcy Exercise Condition is satisfied prior to the satisfaction of the Merger Exercise Condition or the Merger
Termination Condition, the Call Option shall automatically be exercised pursuant to this Section 2.2(b) without any further action or approval of any kind by any person, including, without limitation, any approval of the Noteholder
Representative, the Required Noteholders, the Board of Directors or any Company Member, immediately prior to the satisfaction of the Bankruptcy Exercise Condition. 
 2.3 Closing. The closing of the acquisition of the Company Interests (the “Closing” and the date of the Closing, the “Closing Date”) pursuant to the Automatic
Redemption or an exercise of the Call Option shall occur: 
 (a) if the Automatic Redemption occurs pursuant to
Section 2.1(b), simultaneously with the Note Redemption and immediately prior to the Merger Closing; 
 (b) if the Call Option is exercised pursuant to Section 2.2(a), on the date specified in the Exercise Notice (and simultaneously with the Note Redemption); provided that such date shall be no
later than the fifth (5th) business day after the
date of the Noteholder Direction; and 

  
 5 

 (c) if the Call Option is exercised pursuant to Section 2.2(b), the Closing
shall be deemed to occur immediately prior to the satisfaction of the Bankruptcy Exercise Condition. 
 2.4 Closing
Deliveries. At the Closing: 
 (a) NextWave shall (i) deliver all right, title and interest in and to 100% of the
Company Interests, free and clear of any encumbrances whatsoever and with no restrictions on the rights and other incidents of record and beneficial ownership pertaining thereto (other than any restrictions pursuant to applicable law or, upon a
Closing pursuant to an exercise of the Call Option, any encumbrances permitted under the Note Exchange Agreement), to the Noteholders, pro rata in accordance with the Amount Owing under the Notes held by each such Noteholder as of such date (the
“Call Date Note Amount”), subject to adjustment pursuant to Section 2.5 below, and (ii) deliver to the Noteholders written assignments, in form and substance reasonably satisfactory to the Required Noteholders, of
any and all rights that NextWave or any of its affiliates holds pertaining to its ownership of the Company Interests being purchased at the Closing, to the extent necessary to vest all such rights in the Noteholders and to cause each of the
Noteholders to become a Company Member; and 
 (b) the Noteholders shall (i) if the Call Option is exercised pursuant to
Section 2.2(a), deliver the Call Exercise Cash Payment to NextWave by means of each Noteholder delivering its pro rata share of the Call Exercise Cash Payment, subject to adjustment pursuant to Section 2.5 below, to NextWave,
and (ii) each deliver a written joinder to the Operating Agreement. 
 Notwithstanding the foregoing, if any Noteholder materially breaches
any agreement of such Noteholder (a “Breaching Noteholder”) in the Note Exchange Agreement or the Intercreditor Agreement, other than a failure to fund the Call Exercise Cash Payment, if applicable, and such breach has not been
remedied prior to the later of (i) ten (10) business days after notice thereof from any Noteholder or the Noteholder Representative and (ii) the expiration of any applicable notice and cure period set forth in the relevant agreement,
such Breaching Noteholder shall be entitled to receive equity distributions in respect of the Company Interests only in an amount up to the Call Date Note Amount of such Breaching Noteholder and upon receipt of the Call Date Note Amount of such
Breaching Noteholder, such Breaching Noteholder shall automatically forfeit (x) all voting rights in respect of its Company Interests, and such Company Interests will no longer be used in any respect in the calculation of Required Members,
(y) any right to designate a member of the Board of Directors, with any such member of the Board of Directors to be replaced by designation of the Required Members, if applicable, and (z) all rights to receive any further distributions as
a Company Member or in respect of the assets of the Company in excess of the Call Date Note Amount of such Company Member. 

2.5 Failure of a Noteholder to Fund. 
 (a) In the event that the Call Option is exercised pursuant to Section 2.2(a) and any Noteholder fails to pay its pro rata share of the Call Exercise Cash Payment (in accordance with the
Amount Owing under the Notes held by such Noteholder as of the Closing), 

  
 6 

 
such Noteholder shall receive equity distributions in respect of the Company Interests only in an amount up to the Call Date Note Amount of such Noteholder and upon receipt of the Call Date Note
Amount of such Noteholder, such Noteholder shall automatically forfeit (i) all voting rights in respect of its Company Interests, and such Company Interests will no longer be used in any respect in the calculation of Required Members,
(ii) any right to designate a member of the Board of Directors, with any such member of the Board of Directors to be replaced by designation of the Required Members, if applicable, and (iii) all rights to receive any further distributions
as a Company Member or in respect of the assets of the Company in excess of the Call Date Note Amount of such Noteholder. Upon payment of distributions sufficient to satisfy the Call Date Note Amount of each Company Member, any subsequent
distributions in respect of the Company Interests shall be made solely in respect of Company Interests held by the Funding Noteholders pro rata in accordance with the amount of the Call Exercise Cash Payment funded by each such Funding Noteholder.

 (b) Notwithstanding the provisions of Section 2.5(a) above, in the event that Douglas Manchester does not fund
his pro rata share of the Call Exercise Cash Payment, Navation, Inc. will have the right to fund such amount in lieu of Douglas Manchester (the “Navation Funding Right”), and upon the payment in full of the Douglas Manchester Call
Date Note Amount, Navation, Inc. shall have the right to vote the Company Interests held by Douglas Manchester, Navation Inc.’s pro rata share of the funded amount of the Call Exercise Cash Payment shall be increased by the amount funded in
lieu of Douglas Manchester, Navation, Inc. shall assume any then-held right of Douglas Manchester to designate a member of the Board of Directors (and may, at its option, retain Douglas Manchester or his designee), and Navation, Inc. shall receive
all further distributions in excess of the Call Date Note Amount that Douglas Manchester otherwise would have been entitled to receive as a Company Member or in respect of the assets of the Company had Douglas Manchester been a Funding Noteholder.
In the event that Navation, Inc. does not fund its pro rata share of the Call Exercise Cash Payment, Douglas Manchester will have the right to fund such amount in lieu of Navation, Inc. (the “Manchester Funding Right”), and upon the
payment in full of the Navation, Inc. Call Date Note Amount, Douglas Manchester shall have the right to vote the Company Interests held by Navation Inc., Douglas Manchester’s pro rata share of the funded amount of the Call Exercise Cash Payment
shall be increased by the amount funded in lieu of Navation, Inc., Douglas Manchester shall assume any then-held right of Navation, Inc. to designate a member of the Board of Directors (and may, at his option, retain Navation, Inc.’s designee),
and Douglas Manchester shall receive all further distributions in excess of the Call Date Note Amount that Navation, Inc. otherwise would have been entitled to receive as a Company Member or in respect of the assets of the Company had Navation, Inc.
been a Funding Noteholder. For the avoidance of doubt, the provisions of this Section 2.5(b) are mutually exclusive with the provisions of Section 2.5(a) such that upon any exercise of the Navation Funding Right or the
Manchester Funding Right, any adjustments to further distributions in excess of the applicable Call Date Note Amount to be made as a result of the exercise of the rights under this Section 2.5(b) shall be made only pursuant to this
Section 2.5(b) and the provisions of Section 2.5(a) shall not apply in respect of such distributions. 

  
 7 

 2.6 FCC Approval. NextWave and the Company shall promptly prepare and file any
applications and other documents, and do all other things necessary, for any approval by the FCC that may be necessary for the transfer of control of the Company to the Noteholders, and immediately after the receipt of any such approval, shall
provide written notice of such approval to the Noteholder Representative and the Noteholders. The Company shall provide the Noteholder Representative written notice of the occurrence of the Governance Effective Date within one (1) business day
thereafter. Promptly after the Closing the Company shall file a consummation notice with the FCC. The parties agree that no control of the Company (as “control” is defined by the rules and regulations of the FCC) shall be exercised by the
Noteholders until the Closing. 
 2.7 Expiration. The Call Option shall not expire or otherwise terminate prior to the
Closing. Upon the Closing following the Automatic Redemption or the exercise of the Call Option, the rights and entitlements of the Noteholders and the obligations of NextWave with respect to the grant of the Call Option shall be fully satisfied.

 2.8 No Transfers or Conversion; Notice. NextWave shall continue to legally and beneficially own all of the Company
Interests and shall not transfer the Company Interests, by operation of law or otherwise, except to the Noteholders upon exercise of the Call Option, or convert the Company Interests to any other security or instrument, including, without
limitation, any security or instrument of the Company or any of its affiliates without the prior written consent of the Required Noteholders. 
 2.9 No Amendment. Neither the Company nor NextWave shall vote for or otherwise consent to any amendment to any of the agreements entered into in connection with, or pursuant to, the Merger
Agreement or the Noteholder Agreements or otherwise take any action without the prior written consent of the Noteholder Representative, which consent shall only be given in accordance with a written instruction from the Required Noteholders, that
(a) would require NextWave to obtain any third party consent to transfer the Company Interests or assign rights pertaining to the ownership of the Company Interests, in either case other than in accordance with this Agreement, or (b) would
otherwise impair NextWave or the Company’s ability to comply with its obligations under this Agreement. 
 SECTION 3

 REPRESENTATIONS AND WARRANTIES OF NEXTWAVE AND THE COMPANY 

NextWave and the Company each hereby represents, warrants and covenants to the Noteholder Representative and the Noteholders, as of the
date hereof and the Closing Date, as follows: 
 3.1 Authorization. Each of NextWave and the Company has all requisite
authority and capacity to execute and deliver this Agreement and any and all instruments necessary or appropriate to effectuate fully the terms and conditions contained herein and the transactions contemplated hereby. This Agreement has been duly
authorized by all necessary action on the part of each of NextWave and the Company and this Agreement has been duly executed and 

  
 8 

 
delivered by each of NextWave and the Company and constitutes the valid and legally binding obligation of each of NextWave and the Company, enforceable in accordance with its terms and
conditions, except as may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors’ rights generally or by equitable principles relating to enforceability, whether considered at law or
equity. 
 3.2 No Violations. The execution and delivery of this Agreement by NextWave and the Company and the
performance by NextWave and the Company of the respective terms of this Agreement (a) does not conflict with or result in a violation of any United States federal, State of New York or State of Delaware regulation or law governing either
NextWave or the Company or either of their organizational documents and (b) would not result in a breach of, constitute a default under, result in the acceleration of, create in any person the right to accelerate, terminate, modify or cancel,
or require any notice under, any material contract to which either NextWave or the Company is a party or by which either NextWave or the Company is bound or to which either NextWave or the Company’s assets are subject, the result of which could
prevent the consummation of the transactions contemplated hereby. 
 3.3 No Consents. Other than the approval that will
be sought from the FCC for the transfer of control of the Company to the Noteholders, no approval, authorization or other action by or filing with any governmental authority of the United States of America, the State of Delaware or the State of New
York having jurisdiction over either NextWave or the Company is required in connection with the execution and delivery of this Agreement and the performance of this Agreement by either NextWave or the Company, or the validity or enforceability
against either NextWave or the Company of this Agreement. 
 3.4 Title; No Encumbrances. NextWave is the lawful record
and beneficial owner of all of the Company Interests, and NextWave has good and marketable title to such securities, free and clear of any encumbrances whatsoever and with no restrictions on the rights and other incidents of record and beneficial
ownership pertaining thereto (other than pursuant to the Noteholder Agreements). There are no outstanding options, warrants, rights (preemptive or otherwise), calls, agreements or commitments to which either NextWave or the Company is a party to
sell or otherwise transfer or dispose of the Company Interests, other than in connection with the proposed transfer to the Noteholders upon exercise of the Call Option. Except pursuant to this Agreement, NextWave has not assigned, sold, distributed,
pledged or otherwise transferred or granted any right (including, without limitation, any right to acquire) or interest in all or any portion of the Company Interests. 
 3.5 No Reliance. Each of NextWave and the Company has independently, and without reliance upon any of the Noteholders or the Noteholder Representative, or any of their respective agents, employees,
officers or directors and without reliance, and based on such information as each of NextWave and the Company and each of their respective advisors have deemed adequate and appropriate, made their own analysis and decision to enter into this
Agreement. Each of NextWave and the Company has had the opportunity to review such information with its advisors. Each of NextWave and the Company acknowledges that neither the Noteholder Representative nor any Noteholder, or any of their respective
agents or 

  
 9 

 
representatives, has given either NextWave or the Company any investment advice, credit information or opinion regarding whether the grant of the Call Option or the sale of the Company Interests
upon exercise thereof is prudent. 
 3.6 Investment Representation. By reason of each of NextWave and the Company’s
business or financial experience, each of NextWave and the Company has the capacity to protect its own interests in connection with the transactions contemplated hereby. NextWave is aware of and has considered the financial and market risk of
selling the Company Interests on the terms set forth in this Agreement and is willing to forego through such sale the potential for future economic gain that might be realized from owning the Company Interests. NextWave is entering into this
Agreement and granting the Call Option (and potentially selling the Company Interests) of NextWave’s own free will with the full understanding of the potential risk and reward associated therewith. 

SECTION 4 

REPRESENTATIONS AND WARRANTIES OF THE NOTEHOLDERS AND THE NOTEHOLDER REPRESENTATIVE 

The Noteholder Representative and each of the Noteholders hereby represents and warrants, severally as to itself only, to NextWave and
the Company, as of the date hereof and the Closing Date, as follows: 
 4.1 Authorization. It has all requisite authority
and capacity to execute and deliver this Agreement and any and all instruments necessary or appropriate to effectuate fully the terms and conditions contained herein and the transactions contemplated hereby. This Agreement has been duly authorized
by all necessary action on its part and this Agreement has been duly executed and delivered by it and constitutes its valid and legally binding obligation, enforceable in accordance with its terms and conditions, except as may be limited by
bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or limiting creditors’ rights generally or by equitable principles relating to enforceability, whether considered at law or equity. 

4.2 No Violations. The execution and delivery of each of this Agreement and the performance by it of the respective terms of this
Agreement (a) does not conflict with or result in a violation of any United States federal, State of New York or State of Delaware regulation or law governing it or its organizational documents and (b) with respect to each Noteholder
(severally as to itself only), would not result in a breach of, constitute a default under, result in the acceleration of, create in any person the right to accelerate, terminate, modify or cancel, or require any notice under, any material contract
to which such party is a party or by which such party is bound or to which such party’s assets are subject, the result of which could prevent the consummation of the transactions contemplated hereby. 

4.3 No Consents. Other than the approval that will be sought from the FCC for the transfer of control of the Company to the
Noteholders, no approval, authorization or other action by or filing with any governmental authority of the United States of America, the State of Delaware or the State of New York having jurisdiction over it is required in connection with the

  
 10 

 
execution and delivery of this Agreement and the performance of this Agreement by it, or the validity or enforceability against it of this Agreement. 

4.4 No Reliance. If a Noteholder, it has independently, and without reliance upon NextWave or the Company, or any of their
respective agents, employees, officers or directors and without reliance, and based on such information as it and its advisors have deemed adequate and appropriate, made its own analysis and decision to enter into this Agreement. If a Noteholder, it
has had the opportunity to review such information with its advisors. If a Noteholder, it acknowledges that neither the NextWave nor the Company, or any of their respective agents or representatives, has given it any investment advice, credit
information or opinion regarding whether the Call Option or the purchase of the Company Interests upon exercise thereof is prudent. For the avoidance of doubt, the Noteholder Representative makes no representations or warranties set forth in this
Section 4.4. 
 4.5 Investment Representation. If a Noteholder, by reason of its business or financial
experience, it has the capacity to protect its own interests in connection with the transactions contemplated hereby. If a Noteholder, it is aware of and has considered the financial and market risk of purchasing the Company Interests on the terms
set forth in this Agreement. If a Noteholder, it is entering into this Agreement (and potentially purchasing the Company Interests) of its own free will with the full understanding of the potential risk and reward associated therewith. For the
avoidance of doubt, the Noteholder Representative makes no representations or warranties set forth in this Section 4.5. 
 SECTION 5 
 MISCELLANEOUS 

5.1 Notices. All notices, requests and other communications hereunder must be in writing and shall be deemed to have been duly
given only if delivered personally or by email or facsimile transmission or internationally recognized courier, to the parties at the following address, email address or facsimile number: 
 if to the Noteholders or the Noteholder Representative: 
 Wilmington Trust,
National Association 
 50 South Sixth Street, Suite 1290 

Minneapolis, Minnesota 95402 
 Attention: Nicholas Tally and Alecia Anderson 
 Facsimile: (612) 217-9651

 Email: aanderson@wilmingtontrust.com 
 if to NextWave: 
 NextWave Wireless LLC 

12264 El Camino Road 
 San Diego, California 92130 

  
 11 

 Attention: Frank Cassou, Esq. 

Facsimile: (858) 704-7825 
 Email: fcassou@nextwave.com 
 with a copy (which shall not constitute effective notice) to:

 Lowenstein Sandler PC 
 1251 Avenue of the Americas 
 New York, New York 10020 

Attention: Marita A. Makinen, Esq. 
 Facsimile: (973) 335-3357 
 Email: mmakinen@lowenstein.com 

if to the Company: 
 NextWave
Holdco LLC 
 12264 El Camino Road 
 San Diego, California 92130 
 Attention: Frank Cassou, Esq. 

Facsimile: (858) 704-7825 
 Email: fcassou@nextwave.com 
 with a copy (which shall not constitute effective notice) to:

 Lowenstein Sandler PC 
 1251 Avenue of the Americas 
 New York, New York 10020 

Attention: Marita A. Makinen, Esq. 
 Facsimile: (973) 335-3357 
 All such notices, requests and other communications shall
(i) if delivered by email or facsimile transmission, be deemed given upon transmission without receipt of notice of failure of transmission, and (ii) if delivered personally or by internationally recognized courier, be deemed given upon
delivery, in each case at the applicable address referenced above. Any party hereto may from time to time change such party’s address, facsimile number or other information for the purpose of notices to that party by giving notice specifying
such change to the other parties hereto. 
 5.2 Governing Law. The parties hereto expressly agree that all the terms and
conditions hereof shall be construed under the laws of the State of New York applicable to agreements made and to be performed entirely therein (including Section 5-1401 of the General Obligations Law of the State of New York), without
regard to conflict of law principles that would result in the application of the laws of another jurisdiction. 

  
 12 

 5.3 Amendment. This Agreement may be amended, supplemented or modified only by a
written instrument duly executed by or on behalf of NextWave, the Company and the Required Noteholders. 
 5.4 Waiver.
Any term or condition of this Agreement may be waived at any time by the party hereto that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the party
waiving such term or condition. No waiver by any party hereto of any term or condition of this Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of the same or any other term or condition of this Agreement on
any future occasion. No delay or omission in the exercise of any power, remedy or right herein provided or otherwise available to any party hereto will impair or affect the right of such party thereafter to exercise the same. Any extension of time
or other indulgence granted to any party hereto will not otherwise alter or affect any power, remedy or right with respect to any other party hereto, or the obligations of the party to whom such extension or indulgence is granted. 

5.5 Invalid Provisions. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any law, and if
the rights or obligations of any party hereto under this Agreement shall not be adversely affected thereby, (a) such provision shall be fully severable, (b) this Agreement shall be construed and enforced as if such illegal, invalid or
unenforceable provision had never comprised a part hereof, and (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance
herefrom. 
 5.6 Entire Agreement. This Agreement contains the entire understanding of the parties with respect to its
subject matter and supersedes, merges and voids all other agreements between or among any of the parties with respect to such subject matter. 
 5.7 No Assignment; Binding Effect. Except as expressly set forth herein, neither this Agreement nor any right, interest or obligation hereunder may be assigned by any party hereto without the prior
written consent of the other parties hereto and any attempt to do so shall be void; provided that any Noteholder may assign its rights hereunder in connection with any transfer of Notes permitted by the Note Exchange Agreement; provided further that
the transferee shall execute a joinder to this Agreement in connection with any such transfer. Subject to the preceding sentence, this Agreement is binding upon, inures to the benefit of and is enforceable by the parties hereto and their respective
successors permitted transferees and assigns. 
 5.8 Third Party Beneficiaries. This Agreement shall be binding upon and
inure solely to the benefit of the parties hereto, their respective successors and permitted assigns, and nothing herein, express or implied, is intended to or shall confer upon any other persons any legal or equitable right, benefit, or remedy of
any nature whatsoever, except as expressly set forth herein. 
 5.9 Construction. Every term and provision of this
Agreement shall be construed simply according to its fair meaning and not strictly for or against any party hereto. 

  
 13 

 5.10 Headings. The headings used in this Agreement have been inserted for convenience
of reference only, and are not intended to describe, interpret, define or limit the scope, extent or intent of this Agreement or any provision hereof. 
 5.11 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 5.12 Attorney’s Fees. As between the Noteholders, the Company and NextWave, in the event of any action for the
breach of this Agreement or misrepresentation by any party, the prevailing party shall be entitled to reasonable attorney’s fees, costs and expenses incurred with respect to such action. 

5.13 Termination. This Agreement shall terminate immediately after the Closing following the Automatic Redemption. 

[Signature Page Follows] 

  
 14 

 IN WITNESS WHEREOF, the parties hereto have executed and entered into this Agreement
as of the day first above set forth. 
  

			
	NextWave Wireless LLC
		
	By:	 	 /s/ Francis J. Harding

	Name:	 	Francis J. Harding
	Title:	 	Treasurer
	
	NextWave Holdco LLC
		
	By:	 	 /s/ Francis J. Harding

	Name:	 	Francis J. Harding
	Title:	 	Treasurer
	
	 Wilmington Trust, National Association,
 as Noteholder Representative

		
	By:	 	 /s/ Renee Kuhl

	Name:	 	Renee Kuhl
	Title:	 	Vice President

 [Signature page to Call Option Agreement] 

 NOTEHOLDERS: 
 AVENUE INVESTMENTS, L.P. 
 By: Avenue Partners, LLC, its General Partner 

 

			
	By:	 	 /s/ Sonia Gardner

	Name:	 	Sonia Gardner
	Title:	 	Member

  

			
	Address:	 	Avenue Capital Group
		 	 535 Madison Avenue

14th Floor
 New York, NY 10022
 Tel: (212) 878-3568
 Email: rsymington@avenuecapital.com;
bmulhern@avenuecapital.com;
 Attn: Robert Symington
 Brian Mulhern
 Esther Posner

 [Signature page to Call Option Agreement] 

 AVENUE CDP GLOBAL OPPORTUNITIES FUND, L.P. 
 By: Avenue Global Opportunities Fund GenPar, LLC, its General Partner 
  

			
	By:	 	 /s/ Sonia Gardner

	Name:	 	Sonia Gardner
	Title:	 	Member

  

			
	Address:	 	Avenue Capital Group
		 	 535 Madison Avenue

14th Floor
 New York, NY 10022
 Tel: (212) 878-3568
 Email: rsymington@avenuecapital.com;
bmulhern@avenuecapital.com;
 Attn: Robert Symington
 Brian Mulhern
 Esther Posner

 [Signature page to Call Option Agreement] 

 AVENUE INTERNATIONAL MASTER L.P. 
 By: Avenue International Master Fund GenPar, Ltd., its General Partner 
  

			
	By:	 	 /s/ Sonia Gardner

	Name:	 	Sonia Gardner
	Title:	 	Member

  

			
	Address:	 	Avenue Capital Group
		 	 535 Madison Avenue

14th Floor
 New York, NY 10022
 Tel: (212) 878-3568
 Email: rsymington@avenuecapital.com;
bmulhern@avenuecapital.com
 Attn: Robert Symington
 Brian Mulhern
 Esther Posner

 [Signature page to Call Option Agreement] 

 AVENUE SPECIAL SITUATIONS FUND IV, L.P. 
 By: Avenue Capital Partners IV, LLC, its General Partner 
 By: GL Partners IV, LLC, its Managing
Member 
  

			
	By:	 	 /s/ Sonia Gardner

	Name:	 	Sonia Gardner
	Title:	 	Member

  

			
	Address:	 	 Avenue Capital Group
 535
Madison Avenue

14th Floor
 New York, NY 10022
 Tel: (212) 878-3568
 Email: rsymington@avenuecapital.com;
bmulhern@avenuecapital.com;
 Attn: Robert Symington
 Brian Mulhern
 Esther Posner

 [Signature page to Call Option Agreement] 

 SOLA LTD 
  

			
	By:	 	 /s/ Christopher A. Pucillo

	Name:	 	Christopher A. Pucillo
	Title:	 	CEO

  

			
	Address:	 	 Solus Alternative Asset Management LP
 430 Park Avenue, 9th Floor
 New York, New York 10022
 Phone: 212-284-4300
 Fax: 212-284-4338

 [Signature page to Call Option Agreement] 

 SOLUS CORE OPPORTUNITIES MASTER FUND LTD 

 

			
	By:	 	 /s/ Christopher A. Pucillo

	Name:	 	Christopher A. Pucillo
	Title:	 	CEO

  

	Address:	Solus Alternative Asset Management LP 

	    	 430 Park Avenue,
9th Floor 

	    	New York, New York 10022 

	    	Phone: 212-284-4300 

	    	Fax: 212-284-4338 

 [Signature
page to Call Option Agreement] 

 MARIN-FINN LIVING TRUST QTIP TRUST UAD 07/04/01 

 

			
	By:	 	 /s/ Kevin Finn

	Name:	 	Kevin Finn
	Title:	 	Trustee

 Address: 
 [Signature page to Call Option Agreement] 

 ALDEN GLOBAL DISTRESSED OPPORTUNITIES MASTER FUND, L.P. 

By: Alden Global Capital Limited, its investment adviser, 
 By: Alden Global Capital LLC, its sub-adviser 
  

			
	By:	 	 /s/ Jason Pecora

	Name:	 	Jason Pecora
	Title:	 	Managing Director

 Address: 

ALDEN GLOBAL VALUE RECOVERY MASTER FUND, L.P. 
 By: Alden Global Capital Limited, its investment adviser, 
 By: Alden Global Capital LLC, its
sub-adviser 
  

			
	By:	 	 /s/ Jason Pecora

	Name:	 	Jason Pecora
	Title:	 	Managing Director

 Address: 
 [Signature page to Call Option Agreement] 

	
	     /s/ Douglas Manchester

	Douglas F. Manchester

 Address: 
 [Signature page to Call Option Agreement] 

 NAVATION INC. 
  

			
	By:	 	 /s/ Allen Salmasi

	Name:	 	Allen Salmasi
	Title:	 	Chief Executive Officer

 Address: 

Navation, Inc. 
 c/o Mr. Alain Tripod

 15, rue Général-Dufour 

Case Postale 5556 
 CH1211 Genéve 11,

 Switzerland 
 Telephone:
(212) 535-6005 
 Fax: (212) 535-6001 
 asalmasi@neuronstar.com 
 with notice also to: 

Seyfarth Shaw LLP 
 c/o Stanley Block

 620 Eighth Avenue 
 New York, NY
10018-1405 
 Telephone: (212) 218-5561 
 Fax: (917) 344-1216 
 sbloch@seyfarth.com 

[Signature page to Call Option Agreement] 

			
	POLYGON RECOVERY FUND L.P.
	By:	 	Polygon Global Partners LLP, its investment manager
		
	By:	 	 /s/ Reade Griffith

	Name:	 	Reade Griffith
	Title:	 	Principal
	
	Address:

 [Signature page to Call Option Agreement] 

 SCHEDULE A 
 NOTEHOLDERS 
 Avenue-CDP Global Opportunities Fund, L.P. 

Avenue International Master, L.P. 
 Avenue
Investments, L.P. 
 Avenue Special Situations Fund IV, L.P. 
 SOLA LTD 
 Solus Core Opportunities Master Fund Ltd 

Marin-Finn Living Trust QTIP Trust 
 Alden Global
Distressed Opportunities Master Fund, L.P. 
 Alden Global Value Recovery Master Fund, L.P. 

Douglas F. Manchester 
 Navation Inc. 

Polygon Recovery Fund L.P.General Services Agreement

 Exhibit 10.5 
 [***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT 

GENERAL SERVICES AGREEMENT 
 BioClinica Agreement #33602 
 This General Services Agreement (this “Agreement”)
effective as of the last date of signature hereof (the “Effective Date”), by and between BIOCLINICA, INC., a Delaware Corporation, with its principal place of business at 826 Newtown-Yardley Road, Newtown, Pennsylvania, 18940-1721
(“BIOCLINICA”) and Alchemia Oncology Pty Ltd. with its principal place of business at 31 Hi-Tech Court, Brisbane Technology Court, Eight Mile Plains QLD, Australia (“ALCHEMIA”). BIOCLINICA and ALCHEMIA are individually referred
to as a “Party” and collectively as the “Parties”. 
 P U R P O S E 

WHEREAS, BIOCLINICA has certain experience, knowledge and abilities that ALCHEMIA wishes to utilize in developing and expanding various business and
organizational considerations, policy formations and overall strategic planning. 
 WHEREAS, ALCHEMIA is in the trade or business of the
manufacture and sale of pharmaceutical, diagnostic and other scientific materials. 
 WHEREAS, ALCHEMIA has engaged a clinical research
organization (“CRO”) to provide various services in relation to a clinical research trial (“Study”) in accordance with Protocol No. ACO-002 entitled “Randomized double-blind Phase III trial of FOLF(HA)iri,
where irinotecan is administered as “HA-Irinotecan Solution for Infusion” compared with irinotecan in the FOLFIRI regimen for irinotecan-naive metastatic colorectal cancer patients who relapsed after first or second-line therapy or
progressed while on first-line or second-line therapy” (“Protocol”) which will involve medical imaging. (“Protocol”) which will involve medical imaging. 
 WHEREAS BIOCLINICA is willing to provide consulting services to ALCHEMIA and desires to accept the arrangement upon the terms and conditions set forth herein. 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained herein, the Parties agree as follows: 

 

	1.	SCOPE OF SERVICES 

  

	1.1	BIOCLINICA will provide medical imaging core laboratory services to ALCHEMIA as more fully set forth in the attached Exhibit A, which is hereby made part of this
Agreement as if fully included herein (the “Services”). Any special or related service which the Parties agree are outside the scope of the Services to be provided hereunder shall be covered under a separate agreement.

  

	1.2	In providing Services under this Agreement, BIOCLINICA shall report to the ALCHEMIA employee or other person designated by ALCHEMIA and shall coordinate with the CRO.

  

	1.3	BIOCLINICA shall perform its tasks under this Agreement in a timely manner and in accordance with the highest professional standards, by appropriately qualified,
experienced and trained personnel, and the Services and any deliverables from those Services will conform in all respects to all descriptions, specifications and other requirements in and/or referred to in this Agreement. 

 

	1.4	BIOCLINICA warrants that the Services shall conform to and be performed in all respects in accordance with all relevant laws, regulations, orders, directions,
standards, specifications, codes of practice and ethical standards and the requirements of any regulatory authority, applicable and/or incidental to the Services, including compliance with all relevant privacy laws in connection with the collection,
retention and transmission of any personal information of participants in the Study and compliance with good clinical practice. 

  

	1.5	 BIOCLINICA warrants that neither BIOCLINICA, its employees, nor any other person retained by it to perform the Services pursuant to this Agreement,
(i) is under investigation by the FDA for debarment 

  
 1 

	 	
action or is presently debarred pursuant to the Generic Drug Enforcement Act of 1992, as amended (21 U.S.C. §301 et seq), (ii) has a disqualification hearing pending or has been
disqualified by the FDA pursuant to 21 CFR Section 312.70 or its successor provisions, or (iii) has engaged in any conduct or activity that could lead to any of the above-mentioned disqualification or debarment actions. If during the term
of this Agreement BIOCLINICA or any person employed or retained by it to perform the Project Services (A) comes under investigation by FDA for debarment action or disqualification, (B) is debarred or disqualified, or
(C) knowingly engages in any conduct or activity which could lead to any of the above-mentioned disqualification or debarment actions, BIOCLINICA shall immediately notify ALCHEMIA of such actions. For the purposes of this section,
reference to the FDA and the Generic Drug Enforcement Act shall also be deemed a reference to any other governmental or regulatory authorities having jurisdiction over the subject matter of the particular Services or any other laws and regulations
applicable to the Services. BIOCLINICA shall notify ALCEHMIA immediately upon any inquiry concerning, or the commencement of any such proceeding concerning, BIOCLINICA or any of its employees or agents. 

 

	1.6	BIOCLINICA shall perform the Services at BIOCLINICA facilities, such locations set forth on Exhibit A, or other such locations as are mutually agreed by the Parties.

  

	1.7	BIOCLINICA shall maintain complete, up to date and accurate records of all aspects of the Services and their performance and results, including, without limitation,
such records as are required for compliance with clause 1.4 of the Agreement. BIOCLINICA shall retain such records in a readily accessible format for the duration of this Agreement and for a period of 15 years thereafter and shall allow a
representative of ALCHEMIA and any relevant regulatory authority to access, inspect and take copies of them at any time. BIOCLINICA must contact ALCHEMIA thirty (30) days prior to destruction of any Services-related records. ALCHEMIA or its
representatives may inspect BIOCLINICA’s procedures, facilities and records relating to the Services at reasonable times and upon reasonable notice. 

  

	1.8	BIOCLINICA shall use its best commercial efforts to ensure that all hardware, software, operating systems, mechanical devices, electronic devices, and any other
components or items of computer systems (“Software and Systems”) which are used to produce reports and data under this agreement, and all documents and data provided to ALCHEMIA under this Agreement shall be free of bugs, viruses and
errors and compliant with 21 CFR Part 11. ALCHEMA must notify BIOLINICA promptly in writing, and within 30 days following the date (i) on which ALCHEMA first determines that the Software and Systems, or any component thereof, contains any bugs,
viruses and errors and not otherwise compliant with 21 CFR Part 11. BIOCLINICA shall use commercially reasonable efforts to remedy any such bug or failure as soon as is reasonably practicable. BIOCLINICA shall comply with all record keeping
requirements under 21 CFR Part 312 and shall retain any records requested by ALCHEMIA resulting from the Services for the time periods required by law or as set forth by separate agreement. BIOCLINICA shall notify ALCHEMIA thirty (30) days
prior to destruction of any records relating to the Services. 

  

	1.9	BIOCLINICA shall permit ALCHEMIA’s authorized representative(s), and the authorized personnel of regulatory authorities, during regular business hours at the
facility, access to BIOCLINICA’s facility to: 

  

	 	a)	examine and inspect BIOCLINICA’s facilities to assess performance of the Services and to observe the progress of the Services and for quality control/quality
assurance purposes; and 

  

	 	b)	inspect and copy all data and work products relating to the Services 

  

	2.	KEY PERSONNEL 

  

	2.1	 The parties may agree that certain persons are key personnel (“Key Personnel”) for the purposes of this Agreement. BIOCLINICA will use
commercially reasonable efforts to ensure that Key Personnel are maintained in accordance with this Agreement, for the length of the Services. BIOCLINICA warrants that Key Personnel will continue to perform the Services for the term of the Agreement
unless there is reasonable cause, such as voluntary resignation or employee termination for cause or non-performance, death, serious physical or mental condition, illness or injury or disability or medical leave. BIOCLINICA shall notify ALCHEMIA of
any changes in Key Personnel performing the Services, where reasonably possible in writing at least two weeks prior to such change. BIOCLINICA shall as soon as 

  
 2 

	 	
practicable thereafter provide ALCHEMIA with the curriculum vitae of each proposed replacement Key Personnel. ALCHEMIA has the right to approve or reject any changes to Key Personnel proposed,
which approval or rejection shall not be unreasonable. BIOCLINICA shall bear all training costs associated with the assignment associated with any change in replacement of Key Personnel unless the replacement is requested by ALCHEMIA without cause

  

	2.2	For the purposes of this Agreement, Key Personnel are: 

 Claudia Gomez, Project Manager 
 Jennifer Schick, Project Director, Oncology

 Andrea Perrone, M.D., Vice President, Clinical Operations, Medical Director 

 

	2.3	All BIOCLINICA employees or agents who are providing any services in connection with the Services (i) are lawfully employed in compliance with all federal, state,
and local employment, labor and immigration laws, (ii) have executed confidentiality or non-disclosure agreements with terms at least as restrictive as the provisions in this Agreement, (iii) have waived any rights they may be able to
claim with respect to any ownership of any data used in the Services, and (iv) have had and will continue to have any and all applicable withholding or payroll and employment taxes withheld and paid by BIOCLINICA, and BIOCLINICA will continue
to be in such compliance. 

  

	3.	COMPENSATION 

  

	3.1	ALCHEMIA agrees to pay as a fee to BIOCLINICA, for the Services rendered during the project, and BIOCLINICA agrees to accept as full payment, inclusive of all
overheads, taxes and other indirect costs and expenses, the amount and at such times as indicated in Exhibit A. 

  

	3.2	In addition to the fee specified in Exhibit A, ALCHEMIA will reimburse BIOCLINICA for reasonable travel and out-of-pocket expenses related to any
ALCHEMIA-requested business, provided that where such expenses exceed US$5,000, they are approved in advance by ALCHEMIA in writing and are supported by receipts and other proofs of purchase to verify the expense. 

 

	3.3	BIOCLINICA will invoice ALCHEMIA for the Services and out-of-pocket expenses monthly in arrears, in accordance with Exhibit A. All invoices will detail the tasks
completed and will include all relevant backup documentation. ALCHEMIA must pay all correctly rendered invoices within thirty (30) days of receipt of the invoice A 1.5% per month carrying charge will be billed for any undisputed fees and
expenses not paid within thirty (30) days of invoice receipt. 

  

	3.4	All rates of exchange shall be determined by reference to the Oanda foreign currency exchange rate (Oanda.com) for the applicable currencies using the average exchange
rate for the given month in which relevant costs are submitted. 

  

	4.	TAXES 

  

	4.1	The fees and charges detailed in the Appendix do not include all taxes which are to be itemized on relevant invoices. In the event that additional taxes or duties, of
whatever nature (collectively, “Taxes”), are required to be made or withheld in respect of payments made pursuant to this Agreement or any applicable work order by any state, federal, provincial or foreign government, including, but not
limited to, GST and withholding tax, ALCHEMIA shall be required to pay such Taxes in addition to sums due to BIOCLINICA and will provide BIOCLINICA with evidence of payment of the same to the relevant authorities. 

 

	4.2	GST 

  

	 	A.	In this clause 4.2: 

 (i) GST
means GST as defined in A New Tax System (Goods and Services Tax) Act 1999 as amended (GST Act) or any replacement or other relevant legislation and regulations; 
 (ii) words or expressions used in this clause which have a particular meaning in the GST law (as defined in the GST Act, and also including any applicable legislative determinations and Australian
Taxation Office public rulings) have the same meaning, unless the context otherwise requires; 

  
 3 

 (iii) any reference to GST payable by a party includes any corresponding GST payable by the
representative member of any GST group of which that party is a member; 
 (iv) any reference to an input tax credit entitlement
by a party includes any corresponding input tax credit entitlement by the representative member of any GST group of which that party is a member; and 
 (v) if the GST law treats part of a supply as a separate supply for the purpose of determining whether GST is payable on that part of the supply or for the purpose of determining the tax period to which
that part of the supply is attributable, such part of the supply is to be treated as a separate supply 
  

	 	B.	Unless GST is expressly included, the consideration to be paid or provided under any other clause of this Agreement for any supply made under or in connection with this
Agreement does not include GST. 

  

	 	C.	To the extent that any supply made under or in connection with this Agreement is a taxable supply, the GST exclusive consideration otherwise to be paid or provided for
that taxable supply is increased by the amount of any GST payable in respect of that taxable supply and that amount must be paid at the same time and in the same manner as the GST exclusive consideration is otherwise to be paid or provided. A
party’s right to payment under this clause is subject to a valid tax invoice being delivered to the recipient of the taxable supply. 

  

	 	D.	To the extent that a party is required to reimburse or indemnify another party for a loss, cost or expense incurred by that other party, that loss, cost or expense does
not include any amount in respect of GST for which that other party is entitled to claim an input tax credit. 

  

	 	E.	To the extent that any consideration payable to a party under this Agreement is determined by reference to a cost incurred by a party, or is determined by reference to
a price, value, sales, revenue or similar amount, the GST exclusive amount of that cost, price, value, sales, revenue or similar amount must be used. 

  

	5.	INTELLECTUAL PROPERTY 

  

	5.1	It is recognized and understood that certain pre-existing inventions and technologies (“Background IP”) are the separate property of ALCHEMIA or
BIOCLINICA and are not affected by this Agreement, and neither Party shall have any claims to or rights in such separate Background IP of the other. It is also recognized and understood that in the event that any improvements or developments related
to BIOCLINICA’s own Background IP are created by BIOCLINICA during the performance of the Services under this Agreement, including but not limited to BIOCLINICA’s source code, or other unique methodology, such improvements or developments
(“BIOCLINICA IP”) shall be owned by BIOCLINICA. 

  

	5.2	BIOCLINICA agrees that all discoveries, designs, programs, improvements, developments, new concepts, methods, agents, materials, ideas and inventions, whether
patentable or not, including the images (“Intellectual Property”), to the extent that these are not BIOCLINICA IP, arising from the Services, including work performed by persons engaged by BIOCLINICA, shall be the sole property of
ALCHEMIA. BIOCLINICA hereby agrees to promptly disclose all Intellectual Property to ALCHEMIA in writing. Furthermore, BIOCLINICA agrees to provide ALCHEMIA with proper assistance and documentation, at ALCHEMIA’S cost, to enable it to file
patents, copyright or other legal protections for the Intellectual Property and agrees to assign or procure the assignment of all rights in such Intellectual Property to ALCHEMIA and to execute or procure the execution of all such documents
(including waivers of moral rights) as are necessary to vest such intellectual property rights in ALCHEMIA. 

  

	5.3	To the extent that the BIOCLINICA IP is necessary to access, retrieve or use information generated as a result of the Services, BIOCLINCIA grants to ALCHEMIA a
royalty-free, non-exclusive licence with the right to use only by ALCHEMIA, its advisors, consultants or contractors, including the CRO, solely for the purposes of accessing and reviewing the relevant data, without the right to sell, assign, export,
or sublicense such BIOCLINICA IP and any improvements thereto. 

  

	5.4	BIOCLINICA warrants that to the extent that it uses or proposes to use the Intellectual Property of any third party in the provision of the Services, BIOCLINICA has
obtained or will obtain at no further cost to ALCHEMIA, from the relevant third party, all necessary licenses and consents for ALCHEMIA and its advisors, consultants or contractors to use the Intellectual Property for any purpose.

  
 4 

	6.	CONFIDENTIALITY 

  

	6.1	In performing the Services, BIOCLINICA will have access to ALCHEMIA Confidential Information. As used in this Agreement, “ALCHEMIA Confidential
information” means any and all information, data, communications, know-how, reports, and results arising from or disclosed to BIOCLINICA in relation to the performance of the Services under this Agreement, as well as any other information
of a secret or confidential character acquired, made available, disclosed or otherwise made known to BIOCLINICA as a result of this Agreement and relating to ALCHEMIA or any of its affiliated companies and whether of a scientific nature or a
commercial nature. 

  

	6.2	In connection with this Agreement, ALCHEMIA will have access to BIOCLINICA Confidential Information. As used in this Agreement, “BIOCLINICA Confidential
Information” means any and all information indicated as being or which reasonably appears to be, of a confidential nature, including but not limited to any proprietary information relating to BlOCLINICA’s business, operations or
products acquired by ALCHEMIA from BIOCLINICA as a result of this Agreement or from performance of the Services to be rendered hereunder. In this Agreement, “Confidential Information” means both ALCHEMIA Confidential Information and
BIOCLINICA Confidential Information. 

  

	6.3	Each Party agrees that it and its respective employees, officers, directors, investigators (“Representatives”) will not use the other party’s
Confidential Information or disclose same to persons other than as may be necessary to carry out such Party’s duties hereunder. 

  

	6.4	The foregoing obligation shall not apply to information: 

  

	 	A.	Which is known to the receiving Party prior to its receipt thereof from the disclosing Party and that information is not subject to another confidentiality obligation;

  

	 	B.	Which is or lawfully becomes generally available to the public; 

  

	 	C.	Which is lawfully acquired from third parties who have a right to disclose such information; or 

 

	 	D.	Which by mutual agreement in writing of the Parties hereto is released from a confidential status. 

 

	6.5	All employees of a Party who will have access to any of the foregoing information supplied by the disclosing Party have executed or shall have executed prior to
undertaking performance under this Agreement, agreements with the receiving Party requiring them to maintain in confidence all such Confidential Information which they receive. 

 

	6.6	BIOCLINICA agrees that upon termination or expiry of this Agreement or, at ALCHEMIA’s request, irrespective of any claims that BIOCLINICA may have against
ALCHEMIA, it shall return to ALCHEMIA all ALCHEMIA Confidential Information and other materials relating to the Services and the Study and provided by ALCHEMIA, in documentary form and return or destroy any copies thereof made by BIOCLINICA.
Notwithstanding the foregoing, BIOCLINICA may retain copies of any such Information as is reasonably necessary for regulatory and insurance purposes, subject to the ongoing obligation to maintain the confidentiality of such ALCHEMIA Confidential
Information. 

  

	7.	RELATIONSHIP OF PARTIES 

The relationship of BIOCLINICA to ALCHEMIA is that of an independent contractor and nothing in this Agreement shall be construed as
creating any other relationship. Neither BIOCLINICA, nor its employees or its agents are authorized to execute any documents on behalf of ALCHEMIA, nor to hold itself out as an agent or representative of ALCHEMIA. 

 

	8.	AGREEMENT TERM/TERMINATION 

  

	8.1	The term of this Agreement is for the period of time mutually agreed upon by ALCHEMIA and BIOCLINICA and set forth in Exhibit A to complete the Services.

  

	8.2	Termination of this Agreement may be effected upon the giving of thirty (30) days written notice by ALCHEMIA without any specified cause or reason. In the event
that either Party becomes insolvent or bankrupt or commits a breach or default in any terms of this Agreement and such Party fails to remedy the breach or default within thirty (30) days after notification of the breach or default from the
other Party, the Party giving notice may, at its option and in addition to any other remedies it may have in law or in equity, terminate this Agreement by sending written notice of immediate termination to the other Party. 

  
 5 

	8.3	In the event of a termination of this Agreement, ALCHEMIA will be responsible for payments for all work completed at that time of termination. In the event of such
close down, BIOCLINICA shall furnish to ALCHEMIA a written estimate of close-down costs. Where termination is by ALCHEMIA due to a breach of the Agreement by BIOCLINICA, BIOCLINICA will be liable for the close-down costs. 

 

	8.4	With notice of one week at least from the termination of the Agreement, received in writing from ALCHEMIA, BIOCLINICA will transfer all images and other deliverables
resulting from the Services but not yet delivered to ALCHEMIA, to any third party designated by ALCHEMIA or to ALCHEMIA directly, at the cost and expense of ALCHEMIA. 

 

	9.	ARBITRATION 

  

	9.1	Any dispute, controversy or claim arising out of or relating to this Agreement, or the breach, termination, or invalidity thereof (each, a “Dispute”) shall
first be referred by the parties to their respective senior-level executives, or their designees, for attempted resolution through good faith negotiations. Any Disputes that cannot be settled by negotiation between the parties or mediation shall be
finally settled under the Rules of Arbitration of the International Chamber of Commerce (the “ICC Rules”) by one or more arbitrators appointed in accordance with the ICC Rules. 

 

	9.2	Any arbitration proceedings shall take place in New York, New York unless otherwise agreed. 

 

	9.3	The award of the arbitrator(s) shall be by majority vote (if more than one arbitrator was appointed in accordance with the ICC Rules), shall be in writing and shall set
forth the facts found by the arbitrator(s) to exist. The arbitrator(s) are authorized to grant pre-award and post-award interest at commercial rates. NOTWITHSTANDING OTHER PROVISIONS OF THIS AGREEMENT WHICH MAY BE INTERPRETED TO THE CONTRARY, THE
ARBITRATOR(S) APPOINTED HEREIN SHALL NOT HAVE THE AUTHORITY TO GRANT DAMAGES TO EITHER PARTY THAT ARE DISCLAIMED OR LIMITED UNDER THIS AGREEMENT. 

  

	9.4	Aside from the arbitrator(s)’ fees and costs, which shall be shared equally by the parties unless the arbitrator(s) for good cause determine otherwise, each party
will be responsible for paying its own fees and costs (including attorney’s fees) incurred in connection with such arbitration. 

  

	9.5	Each party shall cooperate in providing fully to each other all requested information and documents relating to the arbitration proceedings, except for information and
documents subject to any privilege or to governmental export restrictions. During the arbitration proceedings, which shall be conducted in the English language, except for the matter that is in dispute and under arbitration, this Agreement shall
continue to be implemented by the Parties. 

  

	9.6	The arbitral award must be consistent with the provisions of this Agreement and shall be exclusive, final, and binding upon both Parties, and enforcement of the award
may be carried out in any court or other body of competent jurisdiction. The award of any such arbitral tribunal shall be final and binding upon the parties. Each Party acknowledges and agrees that any decision resulting from the arbitration
proceedings contemplated hereunder would be enforceable in their respective countries pursuant to the New York Convention on Recognition and Enforcement of Foreign Arbitral Awards. Neither party shall seek recourse to a court of law to appeal for
revision of the award. 

  

	10.	INDEMNIFICATION 

  

	10.1	ALCHEMIA Indemnification of BIOCLINICA 

 Except for any item for which BIOCLINICA is responsible to indemnify ALCHEMIA under Section 9.2, ALCHEMIA agrees to defend, indemnify and hold harmless BIOCLINICA and its employees, agents and
subcontractors against and from any claim arising out of bad faith, willful misconduct or negligent acts of ALCHEMIA or its employees, agents and subcontractors or acts which are not in accordance with the terms of this Agreement or with ethical
practices of the consultations specified herein. ALCHEMIA agrees to bear all costs and expenses, including reasonable attorney’s fees, incurred in connection with the defense of any such claim. 

ALCHEMIA shall be promptly notified of any claim being made against BIOCLINICA and BIOCLINICA shall cooperate at the request of ALCHEMIA
in the defense of such claim. 

  
 6 

 ALCHEMIA will not enter into any settlement agreement without the written consent of
BIOCLINICA. 
  

	10.2	BIOCLINICA Indemnification of ALCHEMIA 

 BIOCLINICA agrees to defend, indemnify and hold harmless ALCHEMIA and its employees and agents and subcontractors against and from any third party claims arising out of or in reference to (1) the
infringement of third parties’ intellectual property rights due to the use of the BIOCLINICA IP, (2) the breach of any of the representations or warranties by BIOCLINICA, (3) the failure of BIOCLINICA to meet its obligations under
this Agreement, or (4) the bad faith, willful misconduct or negligent acts of BIOCLINICA and its employees, agents and subcontractors or acts which are not in accordance with the terms of this Agreement or with ethical practices of the
consultations specified herein. BIOCLINICA agrees to bear all costs and expenses, including reasonable attorney’s fees, incurred in connection with the defense of any such third party claim. 

BIOCLINICA shall be promptly notified of any claim being made against ALCHEMIA and ALCHEMIA shall cooperate at the request of BIOCLINICA
in the defense of such claim. BIOCLINICA will not enter into any settlement agreement without the written consent of ALCHEMIA. 
  

	11.	PRIVACY 

 As applicable,
each party shall comply with all applicable laws and regulations, as amended from time to time, with respect to the collection, use, storage and disclosure of any Data (as defined below), including without limitation, the Health Insurance
Portability and Accountability Act of 1996 (“HIPAA”) and its implementing regulations. BIOCLINICA agrees to collect, use and disclose Data with respect to individual study subjects only as allowed by the informed consents, or other
authorization, obtained from such study subject as part of the Services, unless otherwise required by law. Such consents shall permit ALCHEMIA to use a limited data set of patient health information for research purposes, including research for new
medical products, therapies, and procedures. All data obtained on any patient subjects will be furnished to ALCHEMIA in a coded format, which protects the subject’s identity. ALCHEMIA’s ability to review the subjects’ medical records
shall be subject to reasonable safeguards for the protection of confidentiality. ALCHEMIA shall be provided with patient information as allowed by law and will maintain the confidentiality of all such patient information, unless specifically
required to disclose such information by law. It is expected that Data containing patient data from the Services will be furnished to ALCHEMIA without patient names or other patient identifying information. In the event ALCHEMIA comes into contact
with research subjects’ medical records, ALCHEMIA shall hold in confidence the identity of the patient and shall comply with all applicable law(s) regarding the confidentiality of such records 

 

	12.	INSURANCE 

  

	12.1	During the term of this Agreement, BIOCLINICA shall maintain insurance coverage with a reputable insurance company for professional indemnity insurance of not less than
US$5million. 

  

	12.2	BIOCLINICA must provide evidence of such insurance upon request by ALCHEMIA. 

 

	13.	COMMUNICATIONS AND PAYMENTS 

 Any notice or other communication required or permitted under this Agreement shall be in writing and shall be delivered by hand, first class mail, a nationally recognized overnight courier service, or
facsimile transmission, to the Party at the address listed below or to any other address subsequently specified by such Party in writing: 
 To BIOCLINICA: 
 Mark L. Weinstein 

President and CEO 

BIOCLINICA, INC. 

826 Newtown-Yardley Road 
 Newtown, PA 18940 
 Tel: (267) 757-3000 

FAX: (267) 757-3007 

  
 7 

 To ALCHEMIA: 
 Peter Smith 
 Managing Director and CEO 

Alchemia Limited 

3 Hi-Tech Court 

Eight Mile Plains 

Brisbane, 4113, Australia 
 Tel: +61733400200 
 FAX: +61733400222 

Payments — USD-denominated Contract 
 (Fed. I.D. #11-2872047) 
  

			
	 Via mail:
  
 BioClinica, Inc.
 P.O. Box 8500-53917
 Philadelphia, PA 19178-3917
	    	 Via Wire Transfer:
  

BioClinica, Inc.
 Wachovia Bank

Philadelphia, PA, USA
 SWIFT #
PNBPUS33
 Account # 200-001-129-4955

Routing # 031-201-467

 Any such notice shall be effective (i) in the case of hand delivery, when received; (ii) in the
case of an overnight delivery service, on the next business day after being placed in the possession of such delivery service, with delivery charges prepaid; (iii) in the case of the mail, three days after deposit in the postal system, first
class postage prepaid; and (iv) in the case of facsimile transmission, when electronic indication of receipt is received. 
  

	14.	ASSIGNMENT 

 Neither Party
shall have the right to assign this agreement or any of the rights or obligations hereunder without the prior written consent of the other, such consent not to be unreasonably withheld. In no event will such an assignment relieve either Parry of its
obligations under this Agreement. 
  

	15.	LIMITATION OF LIABILITY 

In no event shall BIOCLINICA’s aggregate liability hereunder exceed the amount of AUD$20million except for gross negligence on the
part of ALCHEMIA. 
  

	16.	HEADINGS 

 All section
headings and sub-headings are for convenience only and do not in themselves define a scope of work or specific terms or conditions of this Agreement. 
  

	17.	ENTIRE AGREEMENT 

 This
Agreement, including Exhibit A, constitutes the entire Agreement between the Parties and, except as specified herein, supersedes all prior contracts, agreements and understandings relating to the same subject matter between the Parties. The
Parties intend this Agreement to be a complete statement of the terms of their Agreement and no change or modification of any of the provisions of this Agreement shall be effective unless it is in writing and signed by a duly authorized officer of
BIOCLINICA and ALCHEMIA. ALCHEMIA will not be required to pay for any costs or increased fees associated with any purported change to this Agreement or to the scope of the Services that is not in writing and signed by both parties. 

  
 8 

	18.	WAIVER 

 The failure of a
Party in any instance to insist on the strict performance of the terms of this Agreement shall not be construed to be a waiver or relinquishment of any terms of this Agreement, either at the time of the Party’s failure to insist upon strict
performance or at any subsequent time, and such terms shall continue in full force and effect. 
  

	19.	SEVERANCE 

 Each clause of
this Agreement is a distinct and severable clause and if any clause is deemed illegal, void, or unenforceable, the validity, legality, or enforceability of any other clause or portion of this Agreement shall not be affected thereby. 

 

	20.	GOVERNING LAW 

 The
construction and performance of this Agreement shall be governed by the laws of the New York, New York. 
  

	21.	SURVIVAL 

 Sections 3, 5,
6 and 8 through 20 will survive termination or expiration of this Agreement. 
 In WITNESS WHEREOF, the undersigned Parties have
executed this Agreement on the dates set forth below. 
  

											
		 	BIOCLINICA, Inc.	 		 	ALCHEMIA
						
		 	By:	 	 /s/ Maria T. Kraus
	 		 	By:	 	 /s/ Peter M. Smith

		 	  
	 		 		 	
						
		 	Print:	 	 Maria T.Kraus
	 		 	Print:	 	 Peter M. Smith

		 	  
	 		 		 	
						
		 	Title:	 	 VP & Corporate Controller
	 		 	Title:	 	 CEO

		 	  
	 		 		 	
						
		 	Date:	 	 17 May 2010
	 		 	Date:	 	 10-May-10

		 	  
	 		 		 	
						
		 	By:	 	 /s/ Ted I. Kaminer
	 		 		 	
						
		 	Print:	 	 Ted I. Kaminer
	 		 		 	
						
		 	Title:	 	 CFO
	 		 		 	
						
		 	Date:	 	 18 May 2010
	 		 		 	

  
 9 

 Exhibit A 

 
 

 
  

					
		  	BioClinica Agreement #2010_33602	  	
			
		  	Alchemia Oncology Pty Ltd	  	
			
		  	Medical Imaging Core Laboratory Services in Support of Protocol ACO-002, a Study Entitled: “Randomized double-blind Phase III trial of FOLF(HA)iri, where irinotecan is
administered as “HA-Irinotecan Solution for Infusion” compared with irinotecan in the FOLFIRI regimen for irinotecan-naïve metastatic colorectal cancer patients who relapsed after first or second-line therapy or progressed
while on first-line or second-line therapy.”	  	
			
		  	Prepared for:	  	
		  	 Alchemia Oncology Pty Ltd
 3
Hi-Tech Court
 Brisbane Technology Park

Eight Mile Plains QLD, Australia
	  	
			
		  	 Prepared by:
	  	
		  	 BioClinica, Inc.
 826 Newtown
Yardley Road
 Newtown, PA 18940
	  	
			
		  	 April 15, 2010 (revised)
	  	

 This document contains information that is confidential and proprietary to Alchemia Oncology Pty Ltd and
BioClinica, Inc. It has been prepared solely for the information of Alchemia Oncology Pty Ltd and BioClinica, Inc. and therefore should not be duplicated or otherwise made available to third parties. 

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

	1.	PROJECT SCOPE OF WORK 

Alchemia Oncology Pty Ltd (hereinafter referred to as “ALCHEMIA”) has requested that BioClinica, Inc. and subsidiaries
(hereinafter referred to as “BIOCLINICA”) provide medical imaging core laboratory services in support of Protocol ACO-002. 
  

	1.1.	PROJECT ASSUMPTIONS 

  

	1.1.1.	Core Laboratory Services 

Table 1.1.1. 
  

			
	 General Study Assumptions

	# of Patients	  	330 Patients
	# of Sites	  	 60 Sites:
 Located in Russia, Ukraine, Poland, UK, Bulgaria, Australia

	# of Investigator’s Meetings including location, # of BIOCLINICA representatives attending meeting and # of days assumed for meeting, including travel time	  	 One (1) Meeting: Location to be determined

One (1) Representative
 Two (2) Days

	Type of imaging Performed	  	Contrast-Enhanced CT of the Chest, Abdomen and Pelvis
	
	 CT Data Assumptions

	Total # of Patients with CT	  	100% or 330 Patients
	Average # of Timepoints per patient	  	 7 Timepoints: Baseline, 6 Weeks, 12 Weeks,

18 Weeks, 24 Weeks, 30 Weeks, 42 Weeks,
 54 Weeks, 66 Weeks and 78 Weeks

	Total # of CT Timepoints	  	2,310 Timepoints
	Average # of Files / Anatomical Regions scanned per timepoint	  	3 Files: Chest, Abdomen and Pelvis
	
	 Quantification and Independent Read Plan
Assumptions

	Measurement Criteria	  	Uni-dimensional RECIST
	Independent Read Plan	  	Efficacy and Adjudication Review
	
	 Independent Read Assumptions

	 Efficacy Read

	# of Timepoints Prepared for Review	  	4,620 Timepoints: 2,310 Timepoints per Reader
	# of Independent Reader(s)	  	Two (2) Independent Readers
	
	 Adjudication Read

	% of Timepoints to be Adjudicated	  	15% or 347 Timepoints
	# of Adjudication Readers	  	One (1) Adjudicator
	
	 Read Data Summary

	Overall Total # of Timepoints Prepared for Review	  	4,967 Timepoints
	# of Data Transfers and Frequency, including a test transfer	  	 4 Transfers: Timing to be determined

1 Test Transfer: Timing to be determined

	
	 Disease Progression Notification Assumptions

	# of Notifications	  	 Fax Notification of Disease Progression

to ALCHEMIA and the site
 (assuming 290 notifications)

 BIOCLINICA has assumed that all image data for a given timepoint will be sent to BIOCLINICA from the sites
as the given timepoints are completed. BIOCLINICA will provide directions to the study sites regarding proper shipment of the image data to BIOCLINICA, and will coordinate the transmittal of the data from the site to BIOCLINICA. 

  
  

					
		  	2	  	April 15, 2010

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

 An audit trail will be consistently maintained for each step of the BIOCLINICA process
in compliance with the applicable regulatory requirements including Good Clinical Practice (GCP) and FDA 21 CFR part 11. 
 If
available, ALCHEMIA will provide BIOCLINICA with the final study protocol, subsequent amendments and study case report forms at the start of the study. 
 All original image data sent to BIOCLINICA will be returned to ALCHEMIA upon completion of the project or sooner if no longer required at BIOCLINICA. 

 

	1.2.	PROJECT TIMELINE AND DATA DELIVERY ASSUMPTIONS 

 BIOCLINICA assumes the following timelines: 
 Table 1.2. 

 

			
	 Project Timeline Assumptions

	 BIOCLINICA Project Start
	  	April 2010
	 First Patient Enrolled
	  	August 2010
	 Last Patient Enrolled
	  	August 2011
	 Last Patient Out
	  	January 2013
	 BIOCLINICA Project Complete
	  	March 2013
	 Total Duration of Data Collection
	  	31 Months
	 Total Study Duration
	  	36 Months

 It is essential for timely completion of this project by BIOCLINICA that sites forward data to BIOCLINICA,
on an ongoing basis. Timely quality assurance of the data is not possible if data are not received in a timely manner. BIOCLINICA will notify ALCHEMIA of data transmittal delays and of the potential impact on BIOCLINICA timelines if the delays are
not corrected. 
 ALCHEMIA will be responsible for providing BIOCLINICA with patient enrollment updates as well as participating
site lists on an ongoing basis. These updates should visibly indicate new information since the last send. Incremental updates are preferred or if cumulative updates are sent all incremental changes from the prior report should be identified.

  

	2.	CORE LABORATORY SERVICES 

  

	2.1.	STUDY PREPARATION, SITE SET-UP AND STANDARDIZATION 

  

	2.1.1.	Study Set-Up 

 BIOCLINICA
will perform the following services upon commencement of the study: 
  

	 	•	 	 Preparation and set-up of internal regulatory files 

  

	 	•	 	 Preparation and set-up of required folders on the BIOCLINICA network 

 

	 	•	 	 Preparation and set-up of BioTrackTM 

  
  

					
		  	3	  	April 15, 2010

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

 BioTrackTM is BIOCLINICA’s custom built project tracking database used to
record and report project-related information including site personnel, site equipment and image data status. The database enables a definitive level of tracking and control at every stage of the image data process. BioTrackTM incorporates
automatic logistical checks and quality control measures reducing potential data entry error. A complete, automatically generated audit trail ensures CFR Part 11 compliance and maintains the controls necessary for extracting optimum results for the
data. 
  

	2.1.2.	Site Technical Evaluation and Coordination 

 BIOCLINICA will create a study specific site technical survey in an effort to capture all necessary contact and equipment information. BIOCLINICA will work with the CRO to contact each of the sites to:

  

	 	•	 	 Identify the technologist(s) who will be responsible for protocol implementation at each site 

 

	 	•	 	 Review the site’s imaging equipment and software 

 

	 	•	 	 Review the site’s data transfer capabilities and archival procedures 

 

	 	•	 	 Review the transfer of the imaging data 

  

	 	•	 	 Review the role of BIOCLINICA 

 Upon completion of the contact, the completed site survey will be reviewed for completeness and logged into the tracking database. All communications (Fax, email and/or phone) will be logged, indicating
the date the site was contacted, the method of contact and the number of communication attempts. In the event that any follow up or action items are required as a result of the site survey, BIOCLINICA will capture all related information into the
tracking database. BIOCLINICA will provide ALCHEMIA and the CRO with a summary of the findings from the site surveys to support the site selection process and timelines. 
 If site equipment (hardware or software) is upgraded or changed during the course of the study, it will be the site’s responsibility to inform BIOCLINICA of the upgrade. BIOCLINICA will re-survey the
site and follow up as needed. Additional fees will apply. 
  

	2.1.3.	Development of Imaging Manual and Forms 

 BIOCLINICA will develop an imaging manual including image data transmittal forms, imaging guidelines, data transmittal instructions and site procedures for handling data. These forms are required to
establish an image data audit trail, and are utilized by BIOCLINICA during the data collection and digitization/translation process. This manual will be provided to each of the sites by BIOCLINICA. BIOCLINICA will work with the CRO to define any
translation requirements for the manual and forms. The cost of such translations is indicated on the BIOCLINICA budget. 
  

	2.1.4.	Study Kit Preparation and Provision to Sites 

 BIOCLINICA will prepare a study kit for delivery to the participating sites. The study kit will contain an imaging binder which will include imaging guidelines, instructions regarding data transmittal and
data archival, completed sample transmittal forms, pre-addressed courier waybills, supply re-order forms, a BIOCLINICA contact list, and the actual forms to be used in image data transmittal to BIOCLINICA. In addition to containing the imaging
binder, the study kit may contain archival media for digital data, padded mailers and/or courier mailers, paint pens for masking confidential patient information, and any other client approved study specific materials that are needed per the
protocol. BIOCLINICA will work with the CRO to define any translation requirements for the study kits. The cost of such translations is indicated on the BIOCLINICA budget. 

  
  

					
		  	4	  	April 15, 2010

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

	2.1.5.	Investigator’s Meeting Preparation and Presentation 

 BIOCLINICA will attend and present at the study Investigator Meeting(s) organized by ALCHEMIA and the CRO. 
 BIOCLINICA will prepare a PowerPoint presentation to be presented during the meeting which will include the study requirements, imaging protocol and the process for submission of data to BIOCLINICA.
BIOCLINICA will provide the presentation to ALCHEMIA prior to the meeting for review and approval. BIOCLINICA will also prepare any supporting materials that are required for the meeting. (e.g. hand outs, sample binders). 

During the meeting, BIOCLINICA will review the presentation and field any questions. Reasonable travel costs and expenses for the meeting
will be billed separately. BIOCLINICA has assumed a project manager will be the designated representative at the Investigator’s Meeting. If Senior Technical, Biomedical, or Regulatory personnel attendance is requested, other fees will apply as
specified in table 3.1.1. These personnel include the following persons: 
  

	 	1.	Andrea Perrone, M.D. 

 Vice
President, Clinical Operations 
 Medical Director 

 

	 	2.	Colin G. Miller PhD FICR CSci 

Senior Vice President, Medical Affairs 
  

	2.1.6.	BioTrackTM Web Portal 

BIOCLINICA will provide ALCHEMIA, its designated representatives and the CRO with access to the BioTrackTM Web Portal. The
BioTrackTM Web Portal is a secure, study specific web site that will allow ALCHEMIA to view study documents, access real time project reports and follow the course of study progression within BIOCLINICA. The BioTrackTM Web Portal will be
password protected and ALCHEMIA will have twenty-four (24) hour access to the site. 
  

	2.1.7.	Preparation and Update of Imaging Review Charter 

 BIOCLINICA will make modifications to the Imaging Review Charter (IRC) describing the processes, services, and issues related to the independent radiological assessment. 

 

	2.1.8.	Web-Based Training Sessions 

 BIOCLINICA will participate in web-based site training sessions, organized by ALCHEMIA, to review the imaging procedures, image data collection and handling, transfer and administration procedures
relevant to the imaging section of the study. 
 BIOCLINICA will prepare a PowerPoint presentation and will provide the
presentation to ALCHEMIA and the sites for use in the web-based training. The training sessions will be conducted via teleconference with the support of the web-based presentation. 

The fees for the web-based training include preparation of materials to be presented, participation, and documentation after the training
session as well as any necessary follow up action items. During the training sessions the two (2) representatives will field any questions that may arise. Upon completion of the session, BIOCLINICA will complete any action items that are
necessary with each site. 

  
  

					
		  	5	  	April 15, 2010

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

	2.2.	CENTRALIZED DATA TRANSLATION/DIGITIZATION AND IMAGE STANDARDIZATION 

 

	2.2.1.	Image Data Log-In 

 Upon
receipt of the data, a BIOCLINICA data coordinator will review the data transmittal form provided by the site and will perform a verification check that the correct data has been received. Any discrepancies between the data received and the
information provided on the data transmittal form will be resolved directly with the site. After the data has been QC’d and translated/digitized, the technologist will re-log the data so that a complete audit trail is maintained. BIOCLINICA
will provide ALCHEMIA and its designated representatives with regular reports on image receipt and quality including outstanding issues with site follow up. 
 Throughout the project, BIOCLINICA will track where in the BIOCLINICA process given patient data are found, including: 
  

	 	•	 	 The date the data are received 

  

	 	•	 	 The date the data are QC’d 

  

	 	•	 	 Comments regarding data quality 

  

	 	•	 	 Tracking of Data Clarification Form (DCF) numbers as well as the relevant issues with the data 

 

	 	•	 	 When data are processed 

  

	 	•	 	 The date the data are prepared for reading 

  

	2.2.2.	Image Data Processing and Quality Control 

 Image data review and processing will be performed by on-site qualified technologists. All study image data will be processed and saved into a standard file format, so that the images may be read and
archived digitally. This process may include the following tasks: 
 DIGITAL DATA 

 

	 	•	 	 Translation of digital image data into a standard file format 

 

	 	•	 	 Quality Control of the data for overall scan quality and protocol compliance 

 

	 	•	 	 Confirmation of imaging parameters (e.g., slice thickness, spacing, field of view, etc.) to ensure appropriate data for accurate quantitative analysis
(applicable modalities) 

  

	 	•	 	 Review of file format parameters 

  

	 	•	 	 Evaluation for missing slices 

  

	 	•	 	 Anonymization of imaging data through the removal of site, subject and timepoint identifiers in order to eliminate reader bias

  

	 	•	 	 Notification to ALCHEMIA and participating sites of technical adequacy issues and recommendation of appropriate action(s) to resolve the issues

 FILM DATA (if received) 

 

	 	•	 	 Digitization of film data 

  

	 	•	 	 Quality Control of the data for overall scan quality and protocol compliance 

 

	 	•	 	 Calibration of the image stacks in preparation for analysis 

 

	 	•	 	 Anonymization of imaging data through the removal of site, subject and timepoint identifiers in order to eliminate reader bias

  

	 	•	 	 Notification to ALCHEMIA and participating sites of technical adequacy issues and recommendation of appropriate action(s) to resolve the issues

 A BIOCLINICA representative will generate a Data Clarification Form (DCF) in the event that data
discrepancies are noted during the administrative QC performed as part of the data log-in process or upon the QC of the image data by a technologist. The DCF is generated to document issues with the data including, but not limited to data quality,
protocol compliance issues and missing data. 

  
  

					
		  	6	  	April 15, 2010

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

 The DCF process includes the following: 

 

	 	•	 	 Preparation of DCF including documentation of the issue 

 

	 	•	 	 Preparation and shipment of letter to site, ALCHEMIA and the CRO documenting DCF 

 

	 	•	 	 File the DCF in the appropriate correspondence files 

 

	2.3.	INDEPENDENT READING SERVICES 

  

	2.3.1.	Reading System Development and Preparation 

 BIOCLINICA will develop a custom application to execute the independent read. The development of this application will include the following: 

 

	 	•	 	 Creation of a client user requirement document 

  

	 	•	 	 Creation of a functional user requirement document 

  

	 	•	 	 Full unit testing 

  

	 	•	 	 Program documentation 

  

	 	•	 	 Test script development and execution of test plan 

  

	 	•	 	 Validation report 

  

	 	•	 	 User acceptance testing 

  

	 	•	 	 Validation and testing to ensure the system conforms to regulatory requirements and documentation of all programming and testing

 BIOCLINICA will work in collaboration with ALCHEMIA to design this application. BIOCLINICA requires that the
client user requirement document be finalized at least sixteen (16) weeks prior to the first reading session. Upon written approval of the client user requirement document by ALCHEMIA, BIOCLINICA will begin the actual programming of the
application. 
 In order to allow a sufficient amount of time to prepare the image data, BIOCLINICA requires that all data to be
included in a given read session be resident at BIOCLINICA at least fifteen (15) business days prior to the read session. In the event that data is received after the fifteen (15) day cut-off, BIOCLINICA will make best efforts to include
the data within the given read session. However, depending on when the data is received and/or discrepancies are found, BIOCLINICA cannot guarantee that the data will be included within the read session. In the event of incomplete or missing scans
of patients, BIOCLINICA must notify ALCHEMIA and seek ALCHEMIA’s consent before proceeding with such reads. 
 BIOCLINICA
will conduct a review session prior to the first independent read. Representatives from BIOCLINICA’s Project Management, Clinical Operations and Technical Services departments will attend and participate in this session. Representatives from
the CRO will also be entitled to attend. The review session is conducted in part for the purpose of familiarizing both ALCHEMIA personnel and/or its designated representatives and the reader(s) with the reading application as well as the independent
read design. During this meeting, ALCHEMIA personnel and the independent reader(s) will review the operation of the BioReadTM application including the interrelationship between questions, sessions, and image display utilizing non-study subjects
with relevant image sets. 
 BIOCLINICA will develop a reader manual to be used for this study. This manual will include
information on the use of the reading application, independent read criteria and reader rules. 

  
  

					
		  	7	  	April 15, 2010

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

	2.3.2.	Conduct and Monitoring of the Independent Read 

  

	2.3.2a.	Read Conduct 

 The review
of the image data will be performed by independent radiologists not affiliated with the study either at the location of the independent reader or at a BIOCLINICA site. All reader image assessments will be captured electronically within the reading
system application and will be backed up by BIOCLINICA. 
 Prior to and after a given read, the following will be performed:

  

	 	•	 	 Testing of read equipment 

  

	 	•	 	 Preparation of image data for review including final QC of data and assignment of image identification codes 

 

	 	•	 	 Loading of read database with timepoints for the given read session 

 

	 	•	 	 Read database testing, including display of patient data and corresponding electronic CRFs and QC of the image data loaded for display

  

	 	•	 	 Independent reader training, including review of reader rules prior to the session 

 

	 	•	 	 Read database back-up and export of reader interpretations upon completion of the given session 

 

	2.3.2b.	Read Monitoring 

BIOCLINICA will perform an evaluation of the read results to ensure the adjudication rate does not exceed the threshold determined by
ALCHEMIA and BIOCLINICA. Monitoring is also performed to ensure adherence to the reader rules and the independent read criteria. This evaluation will be conducted on a regular basis as deemed appropriate by BIOCLINICA and as per the read plan.

 The read monitoring process includes an early assessment after a predetermined number of complete cases have been read by both
primary readers and analyzed by the adjudicator. The data will be assessed based on the points of adjudication identified by ALCHEMIA and BIOCLINICA in the imaging charter. In the event that the concordance is not within the parameters expected, the
data will be further analyzed for trends or patterns to determine if the underlying cause is due to a lack of adherence or misinterpretation of the reader rules. If necessary, BIOCLINICA (with approval from ALCHEMIA) will conduct a training session
with the readers and the adjudicator in attendance to review specific cases and subsequently revise the reader rules to add more clarity, if required. 
 Further discussion is required between BIOCLINICA and ALCHEMIA in order to finalize the read plan. 
 BIOCLINICA will issue a fax notification of disease progression to ALCHEMIA and site upon completion of review. 
  

	2.3.3.	Study Report (On an Interim Basis Agreed Upon by ALCHEMIA and at Study End) 

BIOCLINICA will prepare a study report, which will include: 

 

	 	•	 	 A description of the core lab procedures 

  

	 	•	 	 A description of the read system 

  

	 	•	 	 A description of the read plan 

  

	 	•	 	 Documentation of any issues during the conduct of the project and any noted Protocol violations discovered by BIOCLINICA 

 

	 	•	 	 Quality control documentation 

 BIOCLINICA shall deliver the study report to ALCHEMIA within thirty (30) business days following completion of the reading of all study patients. ALCHEMIA will have one (1) review period of
twenty (20) business days, following delivery of the report. Within this period, ALCHEMIA may request within-scope revisions to the report and BIOCLINICA will make requested within-scope revisions at no additional cost to ALCHEMIA. 

  
  

					
		  	8	  	April 15, 2010

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

	2.4.	DATA MANAGEMENT SERVICES 

  

	2.4.1.	Development of Export Program 

 The results obtained from the independent read, including lesion measurement results if applicable, will be provided to ALCHEMIA or its designated agent/representatives in BIOCLINICA’s standard
export format (SAS). BIOCLINICA will provide a detailed export specification document describing the data sets to be provided. Upon written approval of this specification document by ALCHEMIA, BIOCLINICA will begin the actual programming and
validation of the export program. 
 In the event ALCHEMIA requests a custom export format, a new export specification will be
developed by BIOCLINICA in collaboration with ALCHEMIA. The additional time and costs associated with a custom export will be calculated in accordance with table 3.1.1. of this Exhibit A. 

 

	2.4.2.	On-going Data Cleaning 

BIOCLINICA will work in collaboration with ALCHEMIA at the start of the study to define protocol-specific fields to be checked at
regularly scheduled intervals. This may include the following: 
  

	 	•	 	 Demographical information (Site, Subject, Initials, Exam Date(s), etc.) collected by BIOCLINICA against those provided by the client enrollment log

  

	 	•	 	 Logistical date progression (e.g., ensure that the date of Visit 2 is later than Visit 1, no images were acquired later than a Date of Death if
applicable.) 

  

	 	•	 	 Quantitative information 

  

	2.4.3.	Data Exportation 

BIOCLINICA will export these data as SAS datasets unless otherwise specified. BIOCLINICA will perform a final QC of the data prior to
submission to ALCHEMIA. 
 BIOCLINICA will perform a transfer of test data to ensure that ALCHEMIA or its designated
agent/representatives will be able to receive the actual data successfully and will work with ALCHEMIA until the data is successfully transferred. The final data will be sent to ALCHEMIA within ten (10) business days after all the data for a
given export have been acquired. 
 If required, BIOCLINICA will follow up with ALCHEMIA on issues related to each given export
up until ninety (90) days post project completion as defined in Table 1.2. In the event export questions are received after this period, ALCHEMIA will be billed on an ad-hoc basis as deemed appropriate by BIOCLINICA. BIOCLINICA will not perform
any research or follow up on these inquiries without written authorization from ALCHEMIA to proceed. 
  

	2.5.	PROJECT ADMINISTRATION 

  

	2.5.1.	Project Management Services 

 BIOCLINICA will provide in-house project management and administration for this project. A project manager and project team will be assigned to the study. This team may include the following
representatives: 
  

	 	•	 	 Core Laboratory technologist with modality-specific experience 

 

	 	•	 	 Lead Programmer 

  

	 	•	 	 Regulatory QA specialist 

  

	 	•	 	 Team Lead, Data Login 

  

	 	•	 	 Data Coordinator 

  

	 	•	 	 Administrative support staff, as necessary 

  
  

					
		  	9	  	April 15, 2010

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

 The Project Management Team will consist of the following individuals: 

 

	 	•	 	 Claudia Gomez, Project Manager 

  

	 	•	 	 Jennifer Schick, Project Director, Oncology 

  

	 	•	 	 Andrea Perrone, M.D., Vice President, Clinical Operations, Medical Director 

The project team will be supported as needed by regulatory and technical consultants and have access to the full range of clinical study
expertise available at BIOCLINICA. Regular internal project meetings are organized by the project manager to monitor project progress. Administrative personnel provide support to the project managers and are included in the project management fee.
Project management oversees the day to day operations for projects in-house at BIOCLINICA. The assigned project manager serves as the primary BIOCLINICA contact for the project. 

Additional responsibilities include: 
 Communication Plan 
 The project manager will develop a project
communication plan that will describe the processes that will be followed during the course of the study including the levels of communication between BIOCLINICA, ALCHEMIA, the CRO, the sites of the Study, the investigators, relevant regulatory
authorities and other relevant parties involved in the Study. In addition, this document will outline details of the communication network as well as the process to be followed for project issue escalation and resolution. 

Teleconferences 
 The BIOCLINICA project manager will participate in teleconferences at least monthly and as otherwise needed with ALCHEMIA and its agents/representatives to discuss the overall project plan, progress,
issues, timelines etc. The frequency and duration of the teleconferences may vary during the course of the study. 
 Project
Summary Reports 
 The project manager will be responsible for preparing and providing weekly progress reports concerning the
Services. As the Study continues, the parties may determine a less frequent reporting requirement. 
 The project manager will be
responsible for the preparation and delivery of monthly project summary reports which are generated from BioTrackTM. This will include the following standard reports: 

 

	 	•	 	 Budget report — This report includes an outline of the amount spent compared to the budgeted amount 

 

	 	•	 	 Project Information Summary Report — This report includes image sets per timepoint, DCFs per timepoint, and a DCF aging report

  

	 	•	 	 Start Up Tracking Report — This report includes the status of site start up activities including the distribution of study kits to the
participating sites 

  

	 	•	 	 DCF Status Report — This report includes DCF information along with a site and project summary of DCF items 

 

	 	•	 	 Image Set Report including DCFs — This report combines the DCF image set receipt and QC information with DCF information to provide an overall
summary of data received in-house at BIOCLINICA 

  

	 	•	 	 Image Set Report — This report includes a detailed summary outlining the process flow of image data at BIOCLINICA from image data receipt to image
data QC and processing 

  

	 	•	 	 Missing Image Data Report — This report includes the anticipated image sets for any future timepoints as well as any image sets logged with an
exam date but not data received 

 Resource Planning 

The project manager will be responsible for the coordination of in-house and external resources pertaining to the study. 

  
  

					
		  	10	  	April 15, 2010

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

 Process Document 

The project manager will be responsible for the development of an internal project specific work instruction manual. The purpose of this
manual is to provide BIOCLINICA employees a detailed description of the procedures to be utilized during the course of the study. 
  

	2.5.2.	Site and Image Data Management Services 

 BIOCLINICA will provide technical support services to the sites including such assistance as may be required in order to manage, monitor and coordinate the conduct of the imaging section of the study.
BIOCLINICA will interact directly with the CRO and site on image data tracking and follow-up issues as necessary. BIOCLINICA will consistently maintain the image audit trail, including the follow-up of data transmittal form errors and image data
clarifications as necessary. Phone reports, fax, e-mail and/or data clarification forms will be utilized to document communication with the sites. These documents will be filed at BIOCLINICA. 

Image data management services will also include: 
  

	 	•	 	 Preparation, maintenance and cleaning of project tracking database on an ongoing basis in support of the project manager 

 

	 	•	 	 Data tracking reports for the project manager on an ongoing basis 

 

	 	•	 	 Provide summary reports of outstanding issues to the project manager 

 

	 	•	 	 Return of re-writable media to sites on an on-going basis for re-archival 

 

	 	•	 	 Return of data to ALCHEMIA upon study completion 

  

	 	•	 	 Internal filing 

  

	 	•	 	 Back up of image data on an ongoing basis 

 Based on enrollment logs sent from ALCHEMIA, BIOCLINICA and/or its agents representatives will follow up with each participating site on an ongoing basis regarding site surveys, outstanding image data and
image data related queries. In the event that a site becomes unresponsive (as defined below), BIOCLINICA will inform and seek assistance from ALCHEMIA. 
 For sites that default on returning the site survey at the expected time interval, three (3) e-mail and/or Fax reminders will be sent within fifteen (15) business days. For sites that default on
returning image data at the expected time interval, three (3) e-mail and/or Fax reminders will be sent within fifteen (15) business days. Further pursuit will be based on instruction from ALCHEMIA. 

In the event that site technical monitoring visits are deemed appropriate by ALCHEMIA and BIOCLINICA, these will be performed on an ad-hoc
basis and will be documented by trip reports. Such trip reports will be filed at BIOCLINICA as well as provided to ALCHEMIA. Such visits will not incur any additional fee unless the visit has been requested by ALCHEMIA, in which case the fees stated
in table 3.1.1. will apply. 
 Please note, the monthly fee for the above service includes all related expenses for telephone,
copy and Fax services. 
  

	2.6.	PROJECT CLOSE-OUT SERVICES 

  

	2.6.1.	Project Close-Out 

 Upon
completion of the study, BIOCLINICA will perform independent departmental study close-out procedures. Project close-out procedures include the following services: 
  

	 	•	 	 Archive the study binder and destroy any excess supplies 

 

	 	•	 	 Resolve outstanding queries 

  

	 	•	 	 Perform final QC of data before final digital archival 

  
  

					
		  	11	  	April 15, 2010

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

	 	•	 	 Gather study-specific information and materials and forward to BIOCLINICA’s Records Management department 

 

	 	•	 	 Archive all study data from BIOCLINICA network to digital media; one (1) copy for long-term storage, one (1) copy forwarded to
BIOCLINICA’s Records Management department for on-site storage 

  

	 	•	 	 Perform official close-out of study-specific administrative accounts including generation of final invoice 

BIOCLINICA’s Records Management department will facilitate the close-out process by organizing and cataloging project related
documents, including any regulatory or internal BIOCLINICA filings. These materials will be stored off-site in long-term storage for fifteen (15) years unless otherwise directed by ALCHEMIA. 

Please note, the fixed fee for this service includes all related expenses for archival media, return shipment supplies and courier
fees. 

  
  

					
		  	12	  	April 15, 2010

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

	3.	PROJECT FEES AND EXPENSES 

  

	3.1.	PROJECT FEES 

 The
estimated fees provided below are based upon the specific assumptions found within this document. Material alterations to the assumptions, including, but not limited to, a change in the number of patients, amount of data, level of support services
or timeline, will impact final pricing. BIOCLINICA will only charge pro-rata for work performed at the rates quoted. BIOCLINICA fees will increase annually beginning with month 25 of the project as defined by the actual project start date. This
increase will be equivalent to the percent increase in the U.S. Consumer Price Index (CPI). 
  

	3.1.1.	Service Fees 

 Table
3.1.1. 
  

															
	 Section
 No
	  	 Services
	  	Unit Fee	 	  	#
Units	 	  	Cost
Total	 
		  	 Study Preparation Services
	  				  				  			
					
	 2.1.1.
	  	 Study Set-up (including preparation and set-up of internal regulatory files, network files and required fields in
BioTrackTM)
	  	 	[***]	  	  	 	1	  	  	 	[***]	  
					
	 2.1.2.
	  	 Site Technical Evaluation and Coordination
	  	 	[***]	  	  	 	60	  	  	 	[***]	  
					
	 2.1.3.
	  	 Imaging Manual and Form Development (Data transmittal forms, imaging guidelines and transmittal instructions) -
CT
	  	 	[***]	  	  	 	1	  	  	 	[***]	  
					
	 2.1.4.
	  	 Organization of study kit materials and provision to the sites
	  	 	[***]	  	  	 	60	  	  	 	[***]	  
					
	 2.1.5.
	  	 Preparation for Investigator’s Meeting
	  	 	[***]	  	  	 	1	  	  	 	[***]	  
					
	 2.1.5.
	  	 Present at one (1) Investigator’s Meeting. One (1) BIOCLINICA representative, two (2) days including travel: Project
Manager
	  	 	[***]	  	  	 	2	  	  	 	[***]	  
					
	 2.1.5.
	  	 Present at one (1) Investigator’s Meeting. One (1) BIOCLINICA representative, two (2) days including travel: Senior
Biomedical, M.D., Ph.D.
	  	 	[***]	  	  	 	2	  	  	 	[***]	  
					
	 2.1.6.
	  	 Development/Set Up of BioTrackTM Web Portal
	  	 	[***]	  	  	 	1	  	  	 	[***]	  
					
	 2.1.6.
	  	 Maintenance of communication line
	  	 	[***]	  	  	 	36	  	  	 	[***]	  
					
	 2.1.7.
	  	 Charter Modifications
	  	 	[***]	  	  	 	1	  	  	 	[***]	  
					
	 2.1.8.
	  	 Web-based training sessions (Assuming two (2) BIOCLINICA representatives)
	  	 	[***]	  	  	 	2	  	  	 	[***]	  
					
	 2.5.2.
	  	 Site Technical Monitoring Visits — one (1) BIOCLINICA representative, two (2) days including travel
	  	 	[***]	  	  	 	2	  	  	 	[***]	  
					
		  	 Image Data Services
	  				  				  			
					
	 2.2.1.
	  	 Log-in of CT image data, including verification to transmittal forms in order to maintain an image data audit
trail
	  	 	[***]	  	  	 	2,310	  	  	 	[***]	  
					
	 2.2.2.
	  	 Processing of CT data including QC for image quality and protocol compliance, film
digitization (if necessary), masking, query generation and digital archival
	  				  				  			
		  	 Estimate Timepoint Fee Cost Savings = [***]
	  	 	[***]	  	  	 	2,310	  	  	 	[***]	  

 [***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT 

  
  

					
		  	13	  	April 15, 2010

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

 Table 3.1.1. continued 

 

															
	 Section
No
	  	 Services
	  	Unit
Fee	 	  	#
Units	 	  	Cost
Total	 
		  	 Independent Reading Services
	  				  				  			
					
	 2.3.1.
	  	 Program reading system, including validation and testing to ensure the system conforms to regulatory requirements and
documentation of all programming and testing
	  	 	[***]	  	  	 	1	  	  	 	[***]	  
					
	 2.3.1.
	  	 Conduct of protocol-specific reader training session at BIOCLINICA
	  	 	[***]	  	  	 	1	  	  	 	[***]	  
					
	 2.3.1.
	  	 Development of Reader Manual and Reader Rules
	  	 	[***]	  	  	 	1	  	  	 	[***]	  
					
	 2.3.2.
	  	 Preparation of timepoint for reading including final QC, uploading and downloading into read system, reading system
maintenance, read monitoring and independent reader support
	  				  				  			
		  	Tier 1: First Half Timepoints	  	 	[***]	  	  	 	2,484	  	  	 	[***]	  
		  	Tier 2: Second Half Timepoints	  	 	[***]	  	  	 	2,483	  	  	 	[***]	  
		  	Estimate Timepoint Fee Cost Savings = [***]	  				  				  			
					
	 2.3.2.
	  	 Notification of disease progression to ALCHEMIA and the site
	  	 	[***]	  	  	 	290	  	  	 	[***]	  
					
	 2.3.3.
	  	 Development and Preparation of Final Study Report
	  	 	[***]	  	  	 	1	  	  	 	[***]	  
					
		  	 Data Management Services
	  				  				  			
					
	 2.4.1.
	  	 Development/Validation of custom export program
	  	 	[***]	  	  	 	1	  	  	 	[***]	  
					
	 2.4.2.
	  	 Data Cleaning/Maintenance (Running on-going queries prior to scheduled exportation)
	  	 	[***]	  	  	 	27	  	  	 	[***]	  
					
	 2.4.3.
	  	 Data exportation, including final QC prior to submission and follow-up
	  	 	[***]	  	  	 	4	  	  	 	[***]	  
					
	 2.5.1.
	  	 Project Management Services

 
 (Interaction and management of internal
cross-functional teams, including documentation of technical issues, preparation and provision of summary reports)
	  				  				  			
		  	 Start up period - First 6 study months
	  	 	[***]	  	  	 	6	  	  	 	[***]	  
		  	 Remaining study months
	  	 	[***]	  	  	 	30	  	  	 	[***]	  
					
	 2.5.2.
	  	 Site and Image Data Management Services

 
 (Direct site interaction/communication and
image data tracking, including filing of study correspondence and maintaining an image audit trail)
	  				  				  			
		  	 Start up period - First 6 study months
	  	 	[***]	  	  	 	6	  	  	 	[***]	  
		  	 Remaining study months
	  	 	[***]	  	  	 	25	  	  	 	[***]	  
					
	 2.6.1.
	  	 Project Close-Out Services

 
 (Including archival of study materials and
images, management of unresolved queries, preparation of materials for off-site, long-term storage and preparation of final invoice)
	  	 	[***]	  	  	 	1	  	  	 	[***]	  
		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 PROJECT TOTAL
	  				  				  	 	[***]	  
		  		  				  				  	  
	  
	 
	 Project Discount [***]
	  				  				  	 
 	[***]
 	  
  
		  		  				  				  	  
	  
	 
	 PROJECT TOTAL — NET OF DISCOUNT
	  				  				  	 	[***]	  
		  		  				  				  	  
	  
	 

  

	*	In the event BIOCLINICA receives files or series in addition to those listed in the Assumptions Table 1.1.1., the timepoint unit fee may be increased. No such
increase will be applied without the written authorization from ALCHEMIA. 

	**	Discounted Line Item 

[***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT 

  
  

					
		  	14	  	April 15, 2010

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

 BIOCLINICA’s normal hours of operation are Monday through Friday 8:30AM to 6:00PM.
BIOCLINICA will charge a premium on independent reading sessions conducted at a BIOCLINICA site after normal hours of operation and on weekends or holidays. 
  

	3.2.	EXPENSES 

  

	3.2.1.	Miscellaneous Expenses 

The estimated project expenses, in this document, unless otherwise specified, do not include reasonable travel expenses nor expenses for
disks, courier, data archival media, forms printing, translation costs, etc. incurred on behalf of ALCHEMIA. Actual expenses will be billed on a monthly basis. Please see the table below for an estimate of miscellaneous expenses: 

Table 3.2.1. 
  

					
	 Pass Through Item(s)
	  	Estimated
Cost	 
	 Travel, Meals and Hotel:
	  			
	 Investigator’s Meeting: One (1) meeting / One (1) BIOCLINICA representative (If Senior Technical, Biomedical,
or Regulatory personnel attendance is requested, additional fees will apply for travel, meals and hotel)
	  	 	[***]	  
	 Printing:
	  			
	 Data transmittal forms, imaging guidelines, etc.
	  	 
 	[***]
 	  
  
	 Media and Supplies:
	  			
	 Study Kit Supplies: Labels, Binders, Tabs, etc @ [***]/ site (assuming 60 sites)
	  	 	[***]	  
	 Courier:
	  			
	 Study kits- estimated priority @ [***]/ International Site (assuming 60 sites)
	  	 	[***]	  
	 Study report
	  	 	[***]	  
	 Electronic Data Transfer:
	  			
	 Trial Set-up, including routing and transmittal forms
	  	 	[***]	  
	 Transport fees @ [***]/ transfer (assuming approximately 2,310 transfers)
	  	 	[***]	  
	 Translation:
	  			
	 Translation (Text): [***] per language (language to be determined)
	  	 	[***]	  
	 Sub-total
	  	 	[***]	  
		  	  
	  
	 
	 % Administrative Fee
	  	 	[***]	  
		  	  
	  
	 
	 Estimated Expenses Total including administrative fee
	  	 	[***]	  
		  	  
	  
	 

 If ALCHEMIA chooses to use an independent reader not on BIOCLINICA’s preferred reader list or decides
to add readers during the course of the study, additional fees may apply for read system equipment and installation. BIOCLINICA will not order equipment or begin the installation process without the written authorization from ALCHEMIA. 

  
  

					
		  	15	  	April 15, 2010

 [***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT 

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

	3.2.2.	Reader Professional Fees and Expenses 

 BIOCLINICA will prepare all reader agreements and manage all reader professional fees for this study. All such expenses will be passed through to ALCHEMIA on a monthly basis and will include a BIOCLINICA
reader management fee. ALCHEMIA will be responsible for any other read related expenses, including any applicable travel, food and lodging required for the performance of their duties, as described in this document. 

The below assumption is an estimate, actual rates will be based on the negotiations between BIOCLINICA and the given readers with final
approval and sign-off by ALCHEMIA. 
 Table 3.2.2. 

 

					
	 Assumption
	  	Total
Cost	 
	 Efficacy: Assuming [***]/hour/reader Assuming 6 timepoints per hour @ 2,310 timepoints per reader (assuming 2 efficacy
readers — 770 total hours)
	  	 	[***]	  
	 Adjudication: Assuming [***]/hour/reader Assuming 10 timepoints per hour @ 347 timepoints per adjudicator (assuming 1
adjudicator — 35 total hours)
	  	 	[***]	  
	 Central Mock Read Session: Assuming [***] per day Assuming 1 Central Mock Read Session (3 readers — 3
days)
	  	 	[***]	  
	 Reader Management Fee ([***]*
	  	 	[***]	  
		  	  
	  
	 
	 Estimated Reader Professional Fees and Expenses
	  	 	[***]	  
		  	  
	  
	 

  

	*	This fee includes managing the reader contract, coordinating the reader schedule, reader invoices and reader payment. 

 

	3.3.	OVERALL TOTAL PROJECT BUDGET 

  

					
	 	  	Total	 
	 Project Total / Direct Service Fees
	  	 	[***]	  
	 Pass Through Expenses
	  	 	[***]	  
	 Reader Professional Fees
	  	 	[***]	  
		  	  
	  
	 
	 OVERALL TOTAL PROJECT
	  	$	1,379,276	  
		  	  
	  
	 

 [***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT 

  
  

					
		  	16	  	April 15, 2010

			
	Alchemia Oncology Pty Ltd	  	Protocol ACO-002

  

 

	4.	PAYMENT SCHEDULE AND BILLING 

 Table 4. 
  

									
	 Milestone
	  	% Fee	 	  	$ Fee	 
	 Signature of Agreement
	  	 	[***]	  	  	 	[***]	  
	 Remainder of will be billed monthly as follows:
	  				  			
			
	 Fixed monthly fees will be billed on the 1st of the month
	  				  			
			
	 All other units will be billed as work is completed
	  				  			
			
	 The upfront signature of agreement payment will be applied to the final invoices
	  				  			
			
	 *********************************************************************************
	  				  			
			
	 Payment for services is due 30 days from receipt of the invoice
	  				  			
			
	 All pass-through and reader expense invoices will be payable within 30 days from receipt of the invoice
	  				  			

  
  

					
		  	17	  	April 15, 2010

 [***] DENOTES CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00207-of-00352.parquet"}]]